


CURRICULUM VITAE

PAOLA ROGLIANI

**TUTTO QUANTO DICHIARATO NEL PRESENTE CURRICULUM VITAE CORRISPONDE
A VERITÀ, AI SENSI DEGLI ARTICOLI 46 E 47 DEL D.P.R. 445 DEL 2000**

DATA: _____

FIRMA:  _____

CURRICULUM VITAE

PAOLA ROGLIANI

Professore Associato confermato

Malattie dell'Apparato Respiratorio -MED/10-

Dipart. di Medicina Sperimentale e Chirurgia

Università di Roma "Tor Vergata"

Via Montpellier,1 –00133- Roma, Italia

UOC MALATTIE APPARATO RESPIRATORIO

Policlinico Tor Vergata

Viale Oxford, 81 -00133- Roma

+39 06 2090 4656

paola.rogliani@uniroma2.it

Luogo di nascita	Napoli
Data di nascita	19-09-1970
Cittadinanza	Italiana
Stato civile	Coniugata

INCARICHI ATTUALI

- Direttore della di Scuola di Specializzazione in "Malattie dell'Apparato Respiratorio", Dipartimento di Medicina Sperimentali, Università degli Studi di Roma "Tor Vergata".
- Direttore della UOC di Malattie dell'Apparato Respiratorio, Dipartimento Clinico di Emergenza e Accettazione, "Policlinico Tor Vergata" Roma.

FORMAZIONE

Luglio 1988	Maturità Classica con il massimo dei voti.
Ottobre 1994	Laurea in Medicina e Chirurgia presso l'Università degli studi di Roma "Tor Vergata" con 110/110 e lode.
Dicembre 1994	Abilitazione all'esercizio della professione medico-chirurgica nella presso la Seconda Università degli studi di Napoli con 90/90.
Novembre 1998	Specializzazione in "Malattie dell'Apparato Respiratorio" presso l'Università degli studi di Roma "Tor Vergata" con 50/50 e lode.
Gennaio 1999	Borsa di Studio di Perfezionamento all'estero-legge 398/89- area disciplinare gruppo B (Scienze Mediche Applicate), gen-dic1999.

TITOLI ACCADEMICI

Novembre 1999	Ricercatore per il settore scientifico-disciplinare MED/10, Malattie dell'Apparato Respiratorio, presso la Facoltà di Medicina e Chirurgia dell'Università degli Studi di Roma "Tor Vergata".
Luglio 2006	Attribuzione con decreto rettorale del titolo di "Professore Aggregato".
Dicembre 2012	Professore Associato, MED/10, Malattie dell'Apparato Respiratorio, presso la Facoltà di Medicina e Chirurgia dell'Università degli Studi di Roma "Tor Vergata", Dipartimento di Medicina dei Sistemi.
2013- 2015	Direttore Scuola di Specializzazione in Medicina delle Sport, Università degli Studi di Roma "Tor Vergata"
2015- presente	Direttore Scuola di Specializzazione in "Malattie dell'Apparato Respiratorio", Università degli Studi di Roma "Tor Vergata"

ATTIVITA' ISTITUZIONALE d'ATENEO

2013-2020	Responsabile per la Macroarea di Medicina e Chirurgia del Presidio Qualità di Ateneo (PQA), Università degli Studi di ROMA "Tor Vergata".
2016-2020	Commissione paritetica docenti/studenti, Facoltà di di Medicina e Chirurgia, Università degli Studi di ROMA "Tor Vergata".

2016-presente Componente della **Commissione** per la Valorizzazione dei Risultati della Ricerca e per il Trasferimento Tecnologico in composizione '**Brevetti**', Università degli Studi di ROMA "Tor Vergata".

SOCIETA' SCIENTIFICHE

- Socio dell' European Respiratory Society (ERS)
- Socio della Società Italiana di Medicina Respiratoria (ex-SIMeR), Segretario eletto Gruppo Clinica mandato 2016/2018
- Socio della Società italiana di Pneumologia SIP/IRS, Segretario Gruppo Clinica
- Società Italiana di Pneumologia (SIP/IRS), presidente Gruppo BPCO e comorbilità mandato 2019/2021

LINGUA STRANIERA :

Lingua Inglese (livello eccellente)

Lingua Francese (livello buono)

I) ATTIVITÀ DI COORDINAMENTO E DI ORGANIZZAZIONE DI GRUPPI DI RICERCA E LA PARTECIPAZIONE A ESSI;

LINEE DI RICERCA

- Patologia ostruttiva e dismetabolismo
- Le comorbilità nella patologia ostruttiva bronchiale cronica (asma e BPCO): epidemiologia e possibili meccanismi patogenetici.
- Valutazione preclinica e clinica dei nuovi farmaci per il trattamento della patologia ostruttiva bronchiale cronica (BPCO e asma).
- Basi strutturali e funzionali della suscettibilità genetica alle patologie interstiziali polmonari
- Enfisema polmonare: alpha1-Antitripsina e il suo ruolo inibitore dell'elastasi neutrofila.

ATTIVITÀ SCIENTIFICA E DI RICERCA

Dic/2012 -presente	Professore Associato nel gruppo disciplinare MED10 "Malattie dell'Apparato Respiratorio", Dipartimento di Medicina Sperimentale e Chirurgia, Università degli studi di Roma "Tor Vergata".
Sett/2000- Dic/2012	Ricercatore nel gruppo disciplinare MED10 "Malattie dell'Apparato Respiratorio", Dipartimento di Medicina Interna, Università degli studi di Roma "Tor Vergata". (dal 05/2002 al 11/2002 congedo per maternità).
Gen/ 1999- Ago/ 2000	Visiting Fellow presso il "Laboratory of Molecular Immunology", presso l'NHLBI dell'National Institute of Health (NIH) Bethesda, MD -USA- diretto dal Dr Warren J Leonard.
Gen/ 1997- Dic/ 1998	Visiting Fellow presso la Pulmonary and Critical Care Medicine Branch, presso l'NHLBI dell'National Institute of Health (NIH) Bethesda, MD -USA- diretta dal Dr. Joel Moss.
Gen/ 1994- Dic/ 1996	Interna presso il laboratorio di "Cardiologia molecolare e cellulare" dell'Università degli studi di Roma "Tor Vergata" diretto dal Dr. Paolo Di Nardo.
Nov/ 1989- Nov/ 1991	Interna presso il Dipartimento di Biochimica e Biofisica "F. Cetrangolo" della Seconda Università degli studi di Napoli diretta dal Prof. Gennaro Della Pietra.

COLLABORAZIONI SCIENTIFICHE

- 2007 -Presente Collaborazione di ricerca con il Sackler Institute of Pulmonary Pharmacology, King's College London, prof Clive Page.
- 2007 -Presente Collaborazione di ricerca con la Sezione di Farmacologia *Leonardo Donatelli*, Dipartimento di Medicina Sperimentale Facoltà di Medicina e Chirurgia II Università degli Studi della Campania Luigi Vanvitelli, Prof.ssa Maria Gabriella Matera
- 2008- Presente Collaborazione di ricerca con la Division of Respirology, Western University, London, Ontario, Canada, Prof Marco Mura.
- 2010 -Presente Collaborazione di ricerca con le Malattie Respiratorie e Trapianto Polmonare, Università di Siena, Prof.ssa Paola Rottoli / Prof.ssa Elena Bargagli

PREMI/AWARD

- 2010 Premio Miglior ricercatore under 40 dell' XI° Congresso Nazionale della Pneumologia

BREVETTI/INVENZIONI

- 2012** Software applicativo per smartphone, tablet e calcolatori elettronici, "COPDCoRi: applicazione non invasiva per la stima e la previsione del rischio di patologia coronarica nei pazienti affetti da broncopneumopatia cronica ostruttiva (BPCO)". (Autori: **P. Rogliani**, MG Matera, F Romeo, L. Calzetta; depositato alla SIAE n. 2013001671)
- 2020** Brevetto per invenzione industriale "Perossiredossina 6 nel trattamento delle malattie ostruttive dell'apparato respiratorio". Domanda numero: 102020000005605. Data di presentazione: 16/03/2020 (Inventori: **Rogliani Paola**, Lauro Davide, Calzetta Luigino).
- 2020** Brevetto per invenzione industriale "Perossiredossina 6 o un suo analogo sintetico per l'uso come ipoglicemizzante". Domanda numero: 102020000005467. Data di

presentazione: 13/03/2020 (Inventori: Lauro Davide, **Rogliani Paola**, Della Morte David, Capuani Barbara, Pacifici Francesca).

PARTECIPAZIONE e/o RESPONSABILITA' DI STUDI E RICERCHE SCIENTIFICHE
AFFIDATI DA QUALIFICATE ISTITUZIONI PUBBLICHE O PRIVATE

- Componente dell'unità di ricerca del progetto "Genetica della cardiomiopatia ipertrofica " Grant CNR 92. 0330711, 9303391.11
- Componente dell'unità di ricerca del progetto "Role of Nitric Oxide in the pathogenesis of lung disease" Grant NIH 201 HL 02537.04 PCCMB
- Componente dell'unità di ricerca del progetto "Analysis of HLA-DP association with beryllium disease susceptibility in pooled exposed population" Grant DE-FG02-02ER63416
- Componente dell'unità di ricerca del progetto "Role of peptide binding and intracellular signalling diversity of major histocompatibility complex genes in T-cell activation and differentiation in chronic granulomatous disorders" Grant (ISS-NIH) CONV.N.530/F-A15
- Componente dell'unità di ricerca del progetto "Identificazione degli agretopi per i geni del Complesso Maggiore di Istocompatibilità di classe II coinvolti nella suscettibilità alla sarcoidosi e nella evoluzione fibrotica della malattia" PRIN 2004067923_006
- Responsabile di Unità Operativa di ricerca del progetto "Piattaforma Italiana per lo studio delle polimorbilità: scenario epidimologico, aspetti clinici e farmacologici, prospettiva di genere e contesto farmaco-economico", ISS PROGRAMMA CCM 2012
- Componente dell'unità di ricerca del progetto dell'Università di Roma Tor Vergata, Progetto MIUR Smart Cities: Smart domotics for safe and energy-aware assisted living – SEAL: Smart&safe, Energy-aware Assisted Living, in collaborazione con Elica s.p.a., BFT s.p.a. ecc. (2013)
- Project director in the research program on "Pharmacological investigation of the interaction between tiotropium bromide and olodaterol on the contractile tone of human bronchi", funded by Boehringer Ingelheim International GmbH (2015)
- Componente dell'unità di ricerca del Dipartimento di Medicina dei Sistemi dell'Università di Roma "Tor Vergata" del Progetto TELETHON "Clinical efficacy of NIV and modafinil on excessive daytime sleepiness: a multicenter, randomized, double-blind, placebo-controlled clinical trial in DM1"
- Responsabile Unità. Protocollo di Studio SIMeR "Patients Adherence and Long Term

Control.” Promotore: SIMeR Società Italiana di Medicina Respiratoria (2014-2016)

- Responsabile del progetto di ricerca sullo "Studio su modello ex-vivo di bronco umano di interazione farmacologica e sul sinergismo tra corticosteroidi, LABA e LAMA nelle diverse associazioni", finanziato da CHIESI farmaceutici spa (2016-2018)
- Principal investigator, Ricerca Scientifica di Ateneo 2015 "Consolidate the Foundations", progetto dal titolo "Human bronchial hyperresponsiveness in a human ex vivo model of diabetes mellitus"
- Responsabile del progetto di ricerca su "Pharmacological characterization of two novel RHO/ROCK kinase inhibitors and their interaction with long-acting bronchodilator agents in human airway smooth muscle" finanziato da CHIESI farmaceutici spa (2019-2020)
- Responsabile del progetto di ricerca su "Glycopyrronium bromide + indacaterol fumarate + mometasone furoate: characterization of the pharmacological interaction and anti-inflammatory profile in an ex vivo human model of severe asthma." finanziato da Novartis Pharma AG, Switzerland (2019-presente)
- Responsabile del progetto di ricerca su "Proteomic profiling of IPF patients for the development of new BAL based diagnostic and prognostic biomarkers in idiopathic pulmonary fibrosis (IPF) and other interstitial lung disease (ILD)". finanziato da Boehringer Ingelheim Italia S.p.A. (2020-presente)

RESPONSABILITA' SCIENTIFICA PER PROGETTI DI RICERCA INTERNAZIONALI E NAZIONALI, AMMESSI AL FINANZIAMENTO SULLA BASE DI BANDI COMPETITIVI CHE PREVEDANO LA REVISIONE TRA PARI

2013-2015 Progetto MINISTERO delle SALUTE programma CCM 2012 dal titolo "Piattaforma italiana per lo studio delle polimorbidità: scenario epidemiologico, aspetti clinici e farmacologici, prospettiva di genere e contesto farmaco-economico", della durata di 24 mesi. Responsabile Unità Operativa 6 : Prof.ssa Paola Rogliani (Aspetti fisiopatologici e clinici delle polimorbidità respiratorie)

2016-2018 Ricerca Scientifica di Ateneo 2015 "Consolidate the Foundations", progetto dal titolo "Human bronchial hyperresponsiveness in a human ex vivo model of diabetes mellitus"; Principal investigator: Prof.ssa Paola Rogliani

**II) ATTIVITÀ DIDATTICA FRONTALE IN CORSI DI LAUREA, DI LAUREA
MAGISTRALE, DI DOTTORATO DI RICERCA E DI MASTER UNIVERSITARI, PRESSO
UNIVERSITÀ ITALIANE E STRANIERE, NONCHÈ IL COORDINAMENTO DI
INIZIATIVE IN CAMPO DIDATTICO SVOLTE IN AMBITO NAZIONALE E
INTERNAZIONALE;**

- 2013- 2015 **Direttore della Scuola di specializzazione** in “Medicina dello Sport”
Università degli studi di Roma “Tor Vergata”
- 2015-presente **Direttore Scuola di Specializzazione** in “Malattie dell’Apparato
Respiratorio”, Università degli Studi di Roma “Tor Vergata”
- A.A.2006- 2015 Incarico d’insegnamento di Fisiopatologia Respiratoria (modulo), Corso
Integrato Patologia Sistemica I, Corso di Laurea in Medicina e
Chirurgia, dell’Università degli Studi di Roma “Tor Vergata”
- A.A.2015- presente Incarico d’insegnamento di Malattie dell’Apparato Respiratorio, Corso
Integrato Patologia Sistemica I, Corso di Laurea in Medicina e
Chirurgia, dell’Università degli Studi di Roma “Tor Vergata”
- A.A.2006- presente Coordinatore del Corso Integrato di “Malattie dell’Apparato Respiratorio
e Cardiovascolare” del Corso di Laurea specialistica in Scienze e
Tecniche delle attività motorie Preventive ed Adattate , dell’Università
degli Studi di Roma “Tor Vergata”
- A.A.2004- 2021 Incarico d’insegnamento di Malattie dell’Apparato Respiratorio presso il
Corso di Laurea Specialistica in Scienze della Riabilitazione,
dell’Università degli Studi di Roma “Tor Vergata”
- A.A.2005- presente Incarico d’insegnamento di Malattie dell’Apparato Respiratorio presso il
Corso di Laurea in Scienze Infermieristiche , dell’Università degli Studi
di Roma “Tor Vergata”
- A.A.1995- 1998 Attività didattica con seminari monotematici sulla Patologia Respiratoria
presso la Scuola di Specializzazione in Endocrinologia e la Scuola di
Specializzazione in Geriatria
- A.A.2000- presente Attività tutoriale per la formazione scientifica e clinica degli studenti del
Corso di Laurea in Medicina e Chirurgia, Università degli Studi di Roma-
“Tor Vergata”

- A.A.2000- presente Guida nella elaborazione delle tesi di specializzazione ed attività tutoriale per la formazione scientifica e clinica degli specializzandi della Scuola di Malattie dell'Apparato Respiratorio dell'Università degli Studi di Roma "Tor Vergata"
- A.A.2000-presente Incarico d'insegnamento di Metodologia Clinica e di Malattie Respiratorie presso la Scuola di Specializzazione in Malattie dell'Apparato Respiratorio dell'Università degli Studi di Roma "Tor Vergata"
- A.A.2000- presente Incarico d'insegnamento di Malattie Respiratorie presso la Scuola di Specializzazione in Endocrinologia e Malattie Metaboliche dell'Università degli Studi di Roma "Tor Vergata"
- A.A.2002- presente Incarico d'insegnamento presso la Scuola di Specializzazione in Geriatría dell'Università degli Studi di Roma "Tor Vergata"
- A.A.2006- presente Incarico d'insegnamento di Riabilitazione Cardiorespiratoria presso la Scuola di Specializzazione in Cardiologia dell'Università degli Studi di Roma "Tor Vergata"
- A.A.06-07/2012-presente Incarico d'insegnamento di Malattie Respiratorie presso la Scuola di Specializzazione in Medicina dello Sport dell'Università degli Studi di Roma "Tor Vergata"
- A.A.2007- presente Incarico d'insegnamento di Fisiopatologia Respiratoria presso la Scuola di Specializzazione in Chirurgia Toracica dell'Università degli Studi di Roma "Tor Vergata"
- A.A.2007- presente Incarico d'insegnamento di Fisiopatologia Respiratoria presso la Scuola di Specializzazione in Medicina Interna dell'Università degli Studi di Roma "Tor Vergata"

PARTECIPAZIONE AL COLLEGIO DEI DOCENTI DI DOTTORATO

- A.A. 2006-2011 **Dottorato di Ricerca "Fisiopatologia Sperimentale e Medicina Molecolare"** Università degli Studi di ROMA "Tor Vergata"
- A.A. 2011-presente **Dottorato di Ricerca "Medicina Sperimentale e dei Sistemi"** Università degli Studi di ROMA "Tor Vergata".

ATTIVITA' DIDATTICA UFFICIALE PRESSO UNIVERSITÀ STRANIERA

A.A.2009- 2012 Incarico d'insegnamento di Malattie dell'Apparato Respiratorio, Corso Integrato Patologia Sistemica I, presso il **Corso di Laurea in Medicina e Chirurgia** Università "Nostra Signora del Buon Consiglio", Tirana, Albania

ATTIVITA' DIDATTICA UFFICIALE PRESSO UNIVERSITÀ ITALIANA

A.A.2020- *presente* Incarico d'insegnamento di Malattie dell'Apparato Respiratorio, Corso Integrato Patologia Sistemica I, presso il **Corso di Laurea in Medicina e Chirurgia** Università "UniCamillus" - Saint Camillus International University of Health and Medical Sciences-. Roma, Italia

III) ATTIVITÀ IN CAMPO CLINICO RELATIVAMENTE AL SETTORE SCIENTIFICO-DISCIPLINARE MED/10;

- 11/2015-presente **Direttore dell'Unità Operativa Complessa (UOC) di Malattie Respiratorie**, Dipartimento Clinico di Emergenza e Accettazione, "Policlinico Tor Vergata" (Estremo atto conferimento incarico: DDG n.663 del 26.10.2015; DDG n.247 del 20.03.2018)
- 1/2006- 11/2015 **Responsabile dell'Unità Operativa Semplice (UOS) di "Endoscopia Respiratoria"** della UOC di Malattie Respiratorie, Dipartimento Clinico di Medicina, "Policlinico Tor Vergata" (Estremo atto conferimento incarico: DDG n.27 del 8.09.2008)
- 12/2011- 09/2013 Responsabile del Reparto di Malattie dell'Apparato Respiratorio della UOC di Malattie Respiratorie Policlinico Tor Vergata, Roma
- 11/2007- 11/2011 **Responsabile del Day-Hospital dedicato allo Studio delle Interstiziopatie Polmonari e dell'ambulatorio della "Fibrosi polmonare e malattie rare"** della UOC di Malattie Respiratorie, Area Funzionale Aggregata di Medicina, Azienda Ospedaliera Universitaria "Policlinico Tor Vergata"
- 1/2006- 12/2007 Responsabile del Servizio Consulenze Pneumologiche della Disciplina di Malattie Respiratorie, Area Funzionale Aggregata di Medicina, AOU "Policlinico Tor Vergata"
- 7/2004- 2007 Incarico ai fini assistenziali presso l'ambulatorio di Malattie Respiratorie della Disciplina di Malattie Respiratorie diretta dal Prof. C. Saltini, Area Funzionale Aggregata di Medicina, Azienda Ospedaliera Universitaria "Policlinico Tor Vergata"
- 1/2003- 06/2004 **Responsabile del Day-Hospital dedicato allo Studio delle Interstiziopatie Polmonari** presso la Divisione clinicizzata di Malattie Respiratorie, diretta dal Prof. C. Saltini, Università degli studi di Roma "Tor Vergata", presso l'IRCCS "L. Spallanzani" Roma.
- 1/2003- 07/2003 Attività assistenziale in qualità di Dirigente medico di I livello presso l'Ambulatorio di Malattie dell' Apparato Respiratorio della Divisione clinicizzata di Malattie Respiratorie diretta dal Prof. C. Saltini, Università degli studi di Roma "Tor Vergata", presso l'IRCCS "L. Spallanzani" Roma
- 12/ 2000- 12/2002 Attività assistenziale in qualità di Dirigente medico di I livello presso il Reparto di Malattie dell' Apparato Respiratorio della Divisione

clinicizzata di Malattie Respiratorie diretta dal Prof. C. Saltini, Università degli studi di Roma "Tor Vergata", presso l'IRCCS "L. Spallanzani" Roma.

09/2017- presente Riconoscimento centro regione Lazio Policlinico Tor Vergata per **Malattie Rare** DCA n. 413/2017 **Responsabile** dell'Ambulatorio "Fibrosi polmonare e delle Malattie Rare dell'Apparato Respiratorio" per le seguenti patologie:

- RHG010 (FIBROSI POLMONARE IDIOPATICA),
- RH0011 (SARCOIDOSI),
- RG0120 (Ipertensione polmonare arteriosa idiopatica)
- RHG011 (Sindromi Gravi ed Invalidanti con Ipoventilazione Centrale Congenita),
- RH0020 (Emosiderosi Polmonare Idiopatica),
- RH0021 (Proteinosi Alveolare Polmonare Idiopatica),
- RH0022 (Proteinosi Alveolare Polmonare Congenita)

IV) IL CONSEGUIMENTO E LA GESTIONE DI FINANZIAMENTI PER ATTIVITÀ DI RICERCA;

- 2016-2018 Responsabile del progetto di ricerca sullo "Studio su modello ex-vivo di bronco umano di interazione farmacologica e sul sinergismo tra corticosteroidi, LABA e LAMA nelle diverse associazioni", finanziato da CHIESI farmaceutici spa
- 2019-2020 Responsabile del progetto di ricerca su "Pharmacological characterization of two novel RHO/ROCK kinase inhibitors and their interaction with long-acting bronchodilator agents in human airway smooth muscle" finanziato da CHIESI farmaceutici spa
- 2019-presente Responsabile del progetto di ricerca su "Glycopyrronium bromide + indacaterol fumarate + mometasone furoate: characterization of the pharmacological interaction and anti-inflammatory profile in an ex vivo human model of severe asthma." finanziato da Novartis Pharma AG, Switzerland
- 2020-presente Responsabile del progetto di ricerca su "Proteomic profiling of IPF patients for the development of new BAL based diagnostic and prognostic biomarkers in idiopathic pulmonary fibrosis (IPF) and other interstitial lung disease (ILD)". finanziato da Boehringer Ingelheim Italia S.p.A.

RESPONSABILITA' SCIENTIFICA PER PROGETTI DI RICERCA INTERNAZIONALI E NAZIONALI, AMMESSI AL FINANZIAMENTO SULLA BASE DI BANDI COMPETITIVI CHE PREVEDANO LA REVISIONE TRA PARI

- 2013-2015 Progetto MINISTERO delle SALUTE programma CCM 2012 dal titolo "Piattaforma italiana per lo studio delle polimorbidity: scenario epidemiologico, aspetti clinici e farmacologici, prospettiva di genere e contesto farmaco-economico", della durata di 24 mesi. Responsabile Unità Operativa 6 : Prof.ssa Paola Rogliani (Aspetti fisiopatologici e clinici delle polimorbidity respiratorie)
- 2016-2018 Ricerca Scientifica di Ateneo 2015 "Consolidate the Foundations", progetto dal titolo " Human bronchial hyperresponsiveness in a human ex vivo model of diabetes mellitus"; Principal investigator: Prof.ssa Paola Rogliani

V) PARTECIPAZIONE A COMITATI EDITORIALI DI RIVISTE;

COMITATI EDITORIALI

2021- presente	Associate Editor of Respiratory Research
2020-presente	Academic Editor of PLOS ONE (Sections: Pulmonology, Pharmacology)
2021_presente	Editor in chief Journal of Experimental Pharmacolgy
2020- presente	Editorial Board Member of BMC Pulmonary Medicine
2016-presente	Editorial Board of International Journal of Chronic Obstructive Pulmonary Disease
2015-presente	Editorial Board of Journal of Pulmonology and Respiratory Research
2018- 2020	Associate Editor of BMC Pulmonary Medicine
2015- 2020	Associate Editor of Pulmonary Pharmacology and Therapeutics
2013-2020	Editorial Board of COPD Research and Practice
2013-presente	Editorial Board of Ars Pneumologica

PUBLICATIONS:

1. Maione F, Iaccarino F, Sirignano M, Rogliani P, Della Pietra F. "Studio di una variante di α 1- Antitripsina". Acc. Di Scienza Mediche e Chirurgiche (Vol CXL VII feb. 1993)
2. Rossi P. - Senis L. - Contini A. - Nardecchia B. - Rogliani P. - Bisogni V. - Rossi S. "Osservazioni clinico-epidemiologiche sulla tubercolosi polmonare nei pazienti extracomunitari ricoverati". Igiene e Sanità Pubblica, vol. 52, n. 4, luglio-agosto 1996, pp. 271-280.
3. Di Nardo P, Fiaccavento R, Natali A, Minieri M, Sampaolesi M, Fusco A, Janmot C, Cuda G, Carbone A, Rogliani P, Peruzzi G. "Embryonic gene expression in nonoverloaded ventricles of hereditary hypertrophic cardiomyopathic hamsters". Lab Invest. 1997 Nov;77(5):489-502.
4. Mineo TC, Pompeo E, Simonetti G, Sabato AF, Turani F, Rogliani P, De Padova F, Nofroni I. "Unilateral thoracoscopic reduction pneumoplasty for asymmetric emphysema". Eur J Cardiothor Surg. 1998 Jul;14(1):33-9.
5. Novoradovsky A, Brantly ML, Waclawiw MA, Chaudhary PP, Ihara H, Qi L, Eissa NT, Barnes PM, Gabriele KM, Ehrmantraut ME, Rogliani P, Moss J. "Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha1-antitrypsin deficiency". Am J Respir Cell Mol Biol. 1999 Mar;20(3):441
6. Mineo TC, Pompeo E, Rogliani P, Villaschi S, Pistolese C, Simonetti G. "Thoracoscopic reduction pneumoplasty for severe emphysema: do pleural adhesions affect outcome?" Thorac Cardiovasc Surg. 1999 Oct;47(5):288-92.
7. Tesouro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. "Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298". Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2832-5
8. Mineo TC, Pompeo E, Rogliani P, Dauri M, Turani F, Bollero P, Magliocchetti N. "Effect of lung volume reduction surgery for severe emphysema on right ventricular function". Am J Respir Crit Care Med. 2002 Feb 15;165(4):489-94.
9. Amicosante M, Berretta F, Franchi A, Rogliani P, Dotti C, Losi M, Dweik R, Saltini C. "HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells". Eur Respir J. 2002 Nov;20(5):1174-8.

10. Rogliani P, Amicosante M, Berretta F, Dotti C, Bocchino M, O'Donnell KM, Saltini C. Role of the HLA-DP glu 69 and the TNF alpha TNFalpha2 gene markers in susceptibility to beryllium hypersensitivity. *Int J Immunopathol Pharmacol*. 2004 May-Aug;17(2 Suppl):3-10
11. Dotti C, D'Apice MR, Rogliani P, Novelli G, Saltini C, Amicosante M. Analysis of TNF-alpha promoter polymorphisms in the susceptibility to beryllium hypersensitivity. *Sarcoidosis Vasc Diffuse Lung Dis*. 2004 Mar;21(1):29-34
12. Pompeo E, Mineo D, Bollero P, Rogliani P, Ambrogi V, Mineo TC. Completion lobectomy after bilateral lung volume reduction for emphysema: salvage option or fancy? *J Thorac Cardiovasc Surg*. 2004 Apr;127(4):1212-4.
13. Pompeo E, Mineo D, Rogliani P, Sabato AF, Mineo TC. Feasibility and results of awake thoroscopic resection of solitary pulmonary nodules. *Ann Thorac Surg*. 2004 Nov;78(5):1761-8
14. Mineo TC, Pompeo E, Mineo D, Rogliani P, Leonardis C, Nofroni I. Results of unilateral lung volume reduction surgery in patients with distinct heterogeneity of emphysema between lungs. *J Thorac Cardiovasc Surg*. 2005 Jan;129(1):73-9
15. Amicosante M, Berretta F, Rossman M, Butler RH, Rogliani P, van den Berg-Loonen E, Saltini C. Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPglubeta69. *Respir Res*. 2005 Aug 14;6:94.
16. Cazzola M, Matera MG, Rogliani P, Page C. Treating systemic effects of COPD. *Trends Pharmacol Sci*. 2007 Oct;28(10):544-50.
17. Cazzola M, Rogliani P, Curradi G. Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view. *Respir Med*. 2008 Mar;102(3):321-7.
18. Rogliani P, Mura M, Porretta MA and Saltini C. New perspectives in the treatment of idiopathic pulmonary fibrosis. *Therapeutic Advances in Respiratory Disease* 2008; 2; 75
19. Rogliani P, Mura M, Mattia P, Ferlosio A, Farinelli G, Mariotta S, Graziano P, Pezzuto G, Ricci A, Saltini C, Orlandi A. HRCT and histopathologic evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema. *Respir Med*. 2008 Dec;102(12):1753-61

20. Cazzola M, Mura M, Segreti A, Mattei MA, Rogliani P.

Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: forme-fruste of Churg-Strauss syndrome? *Allergy*. 2009 Sep;64(9):1389-90.

21. Matera MG, Calzetta L, Parascandolo V, Curradi G, Rogliani P, Cazzola M. Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. *Pulm Pharmacol Ther*. 2009 Dec;22(6):478-82.

22. Cazzola M, Rogliani P, Curradi G, Segreti A, Ciaprinì C, Pezzuto G, Saltini C. A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD. *Pulm Pharmacol Ther*. 2009 Dec;22(6):522-5.

23. Comandini A, Rogliani P, Nunziata A, Cazzola M, Curradi G, Saltini C. Biomarkers of lung damage associated with tobacco smoke in induced sputum. *Respir Med*. 2009 Nov;103(11):1592-613.

24. Rogliani P, Curradi G, Mura M, Lauro D, Federici M, Galli A, Saltini C, Cazzola M. Metabolic syndrome and risk of pulmonary involvement. *Respir Med*. 2010 Jan;104(1):47-51.

25. Ricci A, Mariotta S, Bronzetti E, Bruno P, Vismara L, De Dominicis C, Laganà B, Paone G, Mura M, Rogliani P, Mastrangelo M, Sciacchitano S, Saltini C. Serum CA 15-3 is increased in pulmonary fibrosis. *Sarcoidosis Vasc Diffuse Lung Dis*. 2009 Jul;26(1):54-63.

26. Sergiacomi G, Bolacchi F, Cadioli M, Angeli ML, Fucci F, Crusco S, Rogliani P, Pezzuto G, Romeo F, Mariano E, Simonetti G. Combined pulmonary fibrosis and emphysema: 3D time-resolved MR angiographic evaluation of pulmonary arterial mean transit time and time to peak enhancement. *Radiology*. 2010 Feb;254(2):601-8.

27. Cazzola M, Calzetta L, Bettoncelli G, Novelli L, Cricelli C, Rogliani P.

Asthma and comorbid medical illness. *Eur Respir J*. 2011 Jul;38(1):42-9.

28. Matera MG, Calzetta L, Rogliani P, Bardaro F, Page CP, Cazzola M. Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. *Pulm Pharmacol Ther*. 2011 Apr;24(2):221-6.

29. Cazzola M, Segreti A, Bettoncelli G, Calzetta L, Cricelli C, Pasqua F, Rogliani P. Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. *Prim Care Respir J*. 2011 Sep;20(3):291-8.
30. Pompeo E, Rogliani P, Tacconi F, Dauri M, Saltini C, Novelli G, Mineo TC; Awake Thoracic Surgery Research Group. Randomized comparison of awake nonresectional versus nonawake resectional lung volume reduction surgery. *J Thorac Cardiovasc Surg*. 2012 Jan;143(1):47-54.e1.
31. Cazzola M, Calzetta L, Bettoncelli G, Cricelli C, Romeo F, Matera MG, Rogliani P. Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study. *Respir Med*. 2012 Feb;106(2):249-56.
32. Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A, Mezzasalma F, Rottoli P, Saltini C, Rogliani P. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. *Eur Respir J*. 2012 Jul;40(1):101-9.
33. Cazzola M, Calzetta L, Rogliani P, Lauro D, Novelli L, Page CP, Kanabar V, Matera MG. High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. *Am J Respir Cell Mol Biol*. 2012 Oct;47(4):509-16.
34. Cazzola M, Capuano A, Rogliani P, Matera MG. Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. *Curr Opin Pharmacol*. 2012 Jun;12(3):300-8.
35. Matera MG, Calzetta L, Passeri D, Rogliani P, Orlandi A. Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity. *Pulm Pharmacol Ther*. 2012 Sep 21.
36. Cazzola M, Rogliani P, Segreti A, Matera MG. An update on bronchodilators in Phase I and II clinical trials. *Expert Opin Investig Drugs*. 2012 Oct;21(10):1489-501.
37. Cazzola M, Segreti A, Rogliani P. Comparative effectiveness of drugs for chronic obstructive pulmonary disease. *Drugs Today (Barc)*. 2012 Dec;48(12):785-94.
38. Pompeo E, Rogliani P, Cristino B, Schillaci O, Novelli G, Saltini C. Awake Thoracoscopic Biopsy of Interstitial Lung Disease. *Ann Thorac Surg*. 2013 Feb;95(2):445-52.

39. Cazzola M, Segreti A, Stirpe E, Puxeddu E, Ora J, Rogliani P, Matera MG. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. *Respir Med.* 2013 Jan;107(1):107-11.
40. Cazzola M, Segreti A, Calzetta L, Rogliani P.
Comorbidities of asthma: current knowledge and future research needs. *Curr Opin Pulm Med.* 2013 Jan;19(1):36
41. Rogliani P, Calzetta L, Rendina EA, Massullo D, Dauri M, Rinaldi B, Capuano A, Matera MG. The influence of propofol, remifentanyl and lidocaine on the tone of human bronchial smooth muscle. *Pulm Pharmacol Ther.* 2013 Jun;26(3):325-
42. Cazzola M, Page CP, Rogliani P, Matera MG. β 2-Agonist Therapy in Lung Disease. *Am J Respir Crit Care Med.* 2013 Apr 1;187(7):690-6.
43. Segreti A, Fiori E, Calzetta L, Sabatini M, Segreti V, Rogliani P, Cazzola M. The effect of indacaterol during an acute exacerbation of COPD. *Pulm Pharmacol Ther.* 2013 Apr 8.
44. Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. *Respir Med.* 2013 Jun;107(6):848-53.
45. Cazzola M, Rogliani P, Matera MG. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2013 Apr;14(6):775-81.
46. Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. *Respir Med.* 2013 Jun;107(6):848-53.
47. Pompeo E, Dauri M; Awake Thoracic Surgery Research Group. Is there any benefit in using awake anesthesia with thoracic epidural in thoracoscopic talc pleurodesis? *J Thorac Cardiovasc Surg.* 2013 Aug;146(2):495-7.
48. Calzetta L, Passeri D, Kanabar V, Rogliani P, Page C, Cazzola M, Matera MG, Orlandi A. Brain Natriuretic Peptide Protects Against Hyperreactivity of Human Asthmatic Airway Smooth Muscle via an Epithelial Cell Dependent Mechanism. *Am J Respir Cell Mol Biol.* 2013 Sep 27.

49. Calzetta L, Page CP, Spina D, Cazzola M, Rogliani P, Facciolo F, Matera MG. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. *J Pharmacol Exp Ther*. 2013 Sep;346(3):414-23.
50. Cazzola M, Calzetta L, Lauro D, Bettoncelli G, Cricelli C, Di Daniele N, Rogliani P. Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit. *Respir Med*. 2013 Sep;107(9):1417-22.
51. Rogliani P, Ora J, Ciapriani C, Senis L, Stirpe E, Cazzola M. Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. *Respir Med*. 2013 Nov 5.
52. Ora J, Calzetta L, Pezzuto G, Senis L, Paone G, Mari A, Portalone S, Rogliani P, Puxeddu E, Saltini C. A 6MWT index to predict O₂ flow correcting exercise induced SpO₂ desaturation in ILD. *Respir Med*. 2013 Dec;107(12):2014-21.
53. Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease. *Expert Opin Pharmacother*. 2013 Dec;14(18):2489-99.
54. Segreti A, Fiori E, Calzetta L, Sabatini M, Segreti V, Rogliani P, Cazzola M. The effect of indacaterol during an acute exacerbation of COPD. *Pulm Pharmacol Ther*. 2013 Dec;26(6):630-4.
55. Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. *Respir Med*. 2013 Jun;107(6):848-53.
56. Cazzola M, Rogliani P, Matera MG. Acclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. *Expert Opin Pharmacother*. 2013 Apr;14(6):775-81.
57. Pompeo E, Dauri M; Awake Thoracic Surgery Research Group. Is there any benefit in using awake anesthesia with thoracic epidural in thoracoscopic talc pleurodesis? *J Thorac Cardiovasc Surg*. 2013 Aug;146(2):495-7.
58. Calzetta L, Page CP, Spina D, Cazzola M, Rogliani P, Facciolo F, Matera MG. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. *J Pharmacol Exp Ther*. 2013 Sep;346(3):414-23.

59. Cazzola M, Calzetta L, Lauro D, Bettoncelli G, Cricelli C, Di Daniele N, Rogliani P. Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit. *Respir Med.* 2013 Sep;107(9):1417-22.
60. Ora J, Calzetta L, Pezzuto G, Senis L, Paone G, Mari A, Portalone S, Rogliani P, Puxeddu E, Saltini C. A 6MWT index to predict O₂ flow correcting exercise induced SpO₂ desaturation in ILD. *Respir Med.* 2013 Dec;107(12):2014-21.
61. Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2013 Dec;14(18):2489-99
62. Rogliani P, Ora J, Ciapri C, Senis L, Stirpe E, Cazzola M.
Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. *Respir Med.* 2013 Nov 5.
63. Matera MG, Calzetta L, Rogliani P, Cesario A, Cazzola M. New Treatments for COPD in the Elderly. *Curr Pharm Des.* 2014 Mar 14
64. Matera MG, Rogliani P, Cazzola M. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2014 May;15(7):961-77
65. Rogliani P, Calzetta L, Segreti A, Barrile A, Cazzola M. Diabetes mellitus among outpatients with COPD attending a university hospital. *Acta Diabetol.* 2014 Apr 13
66. Calzetta L, Rogliani P, Cazzola M, Matera MG. Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond. *Expert Opin Drug Discov.* 2014 Jun;9(6):595-607. Epub 2014 Apr 22.
67. Segreti A, Stirpe E, Rogliani P, Cazzola M. Defining phenotypes in COPD: an aid to personalized healthcare. *Mol Diagn Ther.* 2014 Aug;18(4):381-
68. Cazzola M, Calzetta L, Segreti A, Facciolo F, Rogliani P, Matera MG. Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. *COPD.* 2014 Sep 15

69. Matera MG, Rogliani P, Calzetta L, Cazzola M. Phosphodiesterase Inhibitors for Chronic Obstructive Pulmonary Disease: What Does the Future Hold? *Drugs*. 2014 Oct 10.
70. Segreti A, Calzetta L, Rogliani P, Cazzola M. Umeclidinium for the treatment of chronic obstructive pulmonary disease. *Expert Rev Respir Med*. 2014 Oct 14;14:1-7.
71. Matera MG, Rogliani P, Rinaldi B, Cazzola M. Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. *Expert Rev Clin Pharmacol*. 2015 Jan;8(1):35-41.
72. Matera MG, Rogliani P, Cazzola M. Indacaterol for the treatment of chronic obstructive pulmonary disease. *Expert Opin Pharmacother*. 2015 Jan;16(1):107-15.
73. Cazzola M, Calzetta L, Page CP, Rogliani P, Facciolo F, Gavaldà A, Matera MG. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. *Eur J Pharmacol*. 2014 Dec 15;745:135-43
74. Lipsi R, Rogliani P, Calzetta L, Segreti A, Cazzola M. The clinical use of regenerative therapy in COPD. *Int J Chron Obstruct Pulmon Dis*. 2014 Dec 12;9:1389-1396. eCollection 2014.
75. Matera MG, Cardaci V, Cazzola M, Rogliani P.
Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. *Expert Opin Drug Saf*. 2015 Jan 5:1-9.
76. Rogliani P, Calzetta L, Ora J, Matera MG. Canakinumab for the treatment of chronic obstructive pulmonary disease. *Pulm Pharmacol Ther*. 2015 Apr;31:15-27.
77. Matera MG, Rogliani P, Cazzola M. QVA149(indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. *Expert Opin Pharmacother*. 2015 May;16(7):1079-90.
78. Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. *Pulm Pharmacol Ther*. 2015 Apr 18.

79. Calzetta L, Luongo L, Cazzola M, Page C, Rogliani P, Facciolo F, Maione S, Capuano A, Rinaldi B, Matera MG. Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. *Life Sci.* 2015 Apr 24.
80. Rogliani P, Calzetta L, Ora J, Lipsi R, Segreti A, Matera MG, Cazzola M. Pharmacological assessment of the onset of action of acclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. *Eur J Pharmacol.* 2015 Aug 15;761:383-90
81. Cazzola M, Rogliani P, Sanduzzi A, Matera MG. Influence of ethnicity on response to asthma drugs. *Expert Opin Drug Metab Toxicol.* 2015 Jul;11(7):1089-97.
82. Ricciardolo FL, Blasi F, Centanni S, Rogliani P. Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma. *Pulm Pharmacol Ther.* 2015 Aug;33:1-10
83. Pompeo E, Rogliani P, Palombi L, Orlandi A, Cristino B, Dauri M; Awake Thoracic Surgery Research Group (ATSRG). The complex care of severe emphysema: role of awake lung volume reduction surgery. *Ann Transl Med.* 2015 May;3(8):108.
84. Pompeo E, Cristino B, Rogliani P, Dauri M; Awake Thoracic Surgery Research Group (ATSRG). Urgent awake thoracoscopic treatment of retained haemothorax associated with respiratory failure. *Ann Transl Med.* 2015 May;3(8):112.
85. Cazzola M, Calzetta L, Matera MG, Muscoli S, Rogliani P, Romeo F. Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. *Respir Med.* 2015 Aug;109(8):1019-25
86. Cazzola M, Rogliani P, Matera MG. Cardiovascular disease in patients with COPD. *Lancet Respir Med.* 2015 Aug;3(8):593-5
87. Rogliani P, Lucà G and Lauro D. Chronic obstructive pulmonary disease and diabetes. *COPD Research and Practice* 2015 Aug;1:3 DOI: 10.1186/s40749-015-0005-y
88. Basello K, Pacifici F, Capuani B, Pastore D, Lombardo M, Ferrelli F, Coppola A, Donadel G, Arriga R, Sconocchia G, Bellia A, Rogliani P, Federici M, Sbraccia P, Lauro D, Della-Morte D. Serum- and Glucocorticoid-Inducible Kinase (SGK)1 delay the onset of Endothelial Senescence by Directly Interacting with hTERT. *Rejuvenation Res.* 2016 Feb;19(1):79-89

89. Cazzola M, Coppola A, Rogliani P, Matera MG. Novel glucocorticoid receptor agonists in the treatment of asthma. *Expert Opin Investig Drugs*. 2015 Nov;24(11):1473-82.
90. Cazzola M, Rogliani P, Ora J, Matera MG. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. *Expert Rev Clin Pharmacol*. 2015;8(5):529-39.
91. Cazzola M, Calzetta L, Ora J, Puxeddu E, Rogliani P, Matera MG. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. *Respir Med*. 2015 Oct;109(10):1305-11.
92. Cazzola M, Rogliani P, Matera MG. Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. *Drugs*. 2015 Sep;75(14):1575-85.
93. Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a metaanalysis. *Eur Respir Rev*. 2015 Sep;24(137):451-61.
94. Rogliani P, Matera MG, Cazzola M. Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. *Drugs Today (Barc)*. 2015 Aug;51(8):469-78.
95. Liccardi G, Salzillo A, Calzetta L, Pignatti P, Rogliani P.
Can pet keeping be considered the only criterion of exposure to cat/dog allergens in the first year of life? *Allergol Immunopathol (Madr)*. 2015 Nov 16. pii: S0301-0546(15)00121-4.
96. Cazzola M, Calzetta L, Rogliani P, Puxeddu E, Facciolo F, Matera MG. Interaction between corticosteroids and muscarinic antagonists in human airways. *Pulm Pharmacol Ther*. 2016 Feb;36:1-9.
97. Liccardi G, Salzillo A, Calzetta L, Piccolo A, Rogliani P.
How many systemic reactions to skin prick tests could be preventable in defined conditions? *Ann Allergy Asthma Immunol*. 2016 Feb;116(2):174.
98. Cazzola M, Rogliani P, Ora J, Matera MG. Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. *Expert Opin Pharmacother*. 2016;17(7):977-88.

99. Calzetta L, Rogliani P, Matera MG, Cazzola M. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. *Chest*. 2016 May;149(5):1181-96.
100. Matera MG, Rogliani P, Calzetta L, Cazzola M. Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update. *Drug Saf*. 2016 Jun;39(6):501-8.
101. Liccardi G, Salzillo A, Calzetta L, Piccolo A, Menna G, Rogliani P. Can the presence of cat/dog at home be considered the only criterion of exposure to cat/dog allergens? A likely underestimated bias in clinical practice and in large epidemiological studies. *Eur Ann Allergy Clin Immunol*. 2016 Mar;48(2):61-4.
102. Liccardi G, Salzillo A, Calzetta L, Piccolo A, Rogliani P. Chronic cat allergen exposure and low sensitization: Possible limitations in patient selection? *J Allergy Clin Immunol*. 2016 May;137(5):1621-2.
103. Cazzola M, Calzetta L, Rogliani P, Matera MG. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. *Expert Opin Drug Discov*. 2016 Jul;11(7):733-44.
104. D'Antonio S, Rogliani P, Paone G, Altieri A, Alma MG, Cazzola M, Puxeddu E. An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network. *Int J Mycobacteriol*. 2016 Jun;5(2):244-7.
105. Liccardi G, Salzillo A, Calzetta L, Ora J, Rogliani P. Dog allergen immunotherapy and allergy to furry animals. *Ann Allergy Asthma Immunol*. 2016 Jun;116(6):590.
106. Rogliani P, Calzetta L, Cazzola M, Matera MG. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. *Expert Opin Drug Saf*. 2016 Aug;15(8):1133-46.
107. Salvati, A., Ora, J., Donatucci, B., Rogliani, P. Cardiopulmonary exercise test in athletes and coronary diseases *Medicina dello Sport* 69 (2) June 2016, 289-296
108. Cazzola M, Calzetta L, Puxeddu E, Ora J, Facciolo F, Rogliani P, Matera MG. Pharmacological characterisation of the interaction between glycopyrronium bromide and

indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. *Respir Res.* 2016 Jun 13;17(1):70.

109. Liccardi G, Salzillo A, Calzetta L, Piccolo A, Rogliani P. Assessment of pet exposure by questionnaires in epidemiological studies (but also in clinical practice!): Why the questions should be simplified? *J Asthma.* 2016 Nov;53(9):879-81.

110. Cazzola M, Ora J, Di Paolo A, Puxeddu E, Calzetta L, Rogliani P. Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD. *Pulm Pharmacol Ther.* 2016 Aug;39:48-53.

111. Cazzola M, Rogliani P. Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? *J Allergy Clin Immunol.* 2016 Oct;138(4):977-983.

112. Liccardi G, Salzillo A, Calzetta L, Ora J, Cazzola M, Matera MG, Rogliani P. Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? *J Allergy Clin Immunol Pract.* 2016 Jul-Aug;4(4):791-3.

113. Liccardi G, Salzillo A, Piccolo A, Calzetta L, Rogliani P. Dysfunction of small airways and prevalence, airway responsiveness and inflammation in asthma: much more than small particle size of pet animal allergens. *Ups J Med Sci.* 2016 Aug;121(3):196-7.

114. Rogliani P, Calzetta L, Capuani B, Facciolo F, Cazzola M, Lauro D, Matera MG. Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. *Am J Respir Cell Mol Biol.* 2016 Dec;55(6):804-814.

115. Calzetta L, Orlandi A, Page C, Rogliani P, Rinaldi B, Rosano G, Cazzola M, Matera MG. Brain natriuretic peptide: Much more than a biomarker. *Int J Cardiol.* 2016 Oct 15;221:1031-8.

116. Capuani B, Pacifici F, Pastore D, Palmirota R, Donadel G, Arriga R, Bellia A, Di Daniele N, Rogliani P, Abete P, Sbraccia P, Guadagni F, Lauro D, Della-Morte D. The role of epsilon PKC in acute and chronic diseases: Possible pharmacological implications of its modulators. *Pharmacol Res.* 2016 Sep;111:659-67.

117. Rogliani P, Calzetta L, Cavalli F, Matera MG, Cazzola M. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. *Pulm Pharmacol Ther.* 2016 Oct;40:95-103.

118. Liccardi G, Salzillo A, Calzetta L, Cazzola M, Matera MG, Rogliani P. Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. *Respir Med.* 2016 Aug;117:150-3.

119. Blasi F, Page C, Rossolini GM, Pallecchi L, Matera MG, Rogliani P, Cazzola M. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. *Respir Med.* 2016 Aug;117:190-7.

120. Matera MG, Page C, Rogliani P, Calzetta L, Cazzola M. Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. *Drugs.* 2016 Sep;76(13):1257-70.

121. Liccardi G, Calzetta L, Sapio C, Rogliani P.

Occupational allergy to horse allergens: More than exposure to horses! *Int J Occup Med Environ Health.* 2016;29(5):721-3.

122. Liccardi G, Salzillo A, Calzetta L, Ora J, Rogliani P.

Gastroesophageal reflux and COPD exacerbations: Is cholinergic-mediated oesophago-bronchial reflex a possible link? *Respirology.* 2016 Sep 16

123. Cazzola M, Rogliani P.

LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients. *Evid Based Med.* 2016 Dec;21(6):222.

124. Rogliani P, Puxeddu E, Ciaprini C, Ora J, Onorato A, Pezzuto G, Calzetta L, Cazzola M. The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. *Biomed Res Int.* 2016;2016:4547953.

125. Rogliani P, Ora J, Puxeddu E, Cazzola M. Airflow obstruction: is it asthma or is it COPD? *Int J Chron Obstruct Pulmon Dis.* 2016 Nov 30;11:3007-3013.

126. Liccardi G, Salzillo A, Calzetta L, Piccolo A, Puxeddu E, Rogliani P.

Is Allergic Sensitization to Siberian Hamster Preventable in High-Risk Individuals Who Are Already Sensitized or Exposed to Furry Animals? *J Investig Allergol Clin Immunol.* 2016;26(6):403-405.

127. Tacconi F, Rogliani P, Cristino B, Gilardi F, Palombi L, Pompeo E; Awake Thoracic Surgery Research Group.. Minimalist video-assisted thoracic surgery biopsy of mediastinal tumors. *J Thorac Dis.* 2016 Dec;8(12):3704-3710

128. Cazzola M, Calzetta L, Rogliani P, Matera MG. Tiotropium formulations and safety: a network meta-analysis. *Ther Adv Drug Saf.* 2017 Jan;8(1):17-30

129. Liccardi G, Calzetta L, Salzillo A, Apicella G, Di Maro E, Rogliani P.

What Could the Role of Can f 5 Allergen Be in Dog-Sensitized Patients in "Real Life"? *J Investig Allergol Clin Immunol.* 2017;27(6):397-398

130. Liccardi G, Calzetta L, Salzillo A, Apicella G, Cavalli F, Rogliani P.

Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in "real life"? *J Allergy Clin Immunol Pract.* 2017 Mar - Apr;5(2):535

131. Liccardi G, Calzetta L, Salzillo A, Puxeddu E, Rogliani P.

Relationship between oxytocin/vasopressin and latex in obstetric surgery: how to recognize (and prevent) allergic reactions and differentiate them from side effects? *J Allergy Clin Immunol Pract.* 2017 May - Jun;5(3):873

132. Calzetta L, Rogliani P, Ora J, Puxeddu E, Cazzola M, Matera MG. LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. *Eur Respir Rev.* 2017 Jan 17;26(143)

133. Cazzola M, Calzetta L, Facciolo F, Rogliani P, Matera MG. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. *Respir Res.* 2017 Jan 24;18(1):26

134. Puxeddu E, Cavalli F, Pezzuto G, Teodori E, Rogliani P.

Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression? *Eur Respir J.* 2017 Feb 23;49(2)

135. Rogliani P, Calzetta L, Coppola A, Cavalli F, Ora J, Puxeddu E, Matera MG, Cazzola M. Optimizing drug delivery in COPD: The role of inhaler devices. *Respir Med.* 2017 Mar;124:6-14

136. Cazzola M, Ora J, Rogliani P, Matera MG. Role of muscarinic antagonists in asthma therapy. *Expert Rev Respir Med*. 2017 Mar;11(3):239-253

137. Liccardi G, Calzetta L, Salzillo A, Billeri L, Lucà G, Rogliani P.

Letter to the Editor: Can dog allergen immunotherapy reduce concomitant allergic sensitization to other furry animals? A preliminary experience. *Eur Ann Allergy Clin Immunol*. 2017 Mar;49(2):92-96

138. Pica F, Ciotti M, Maurici M, Buè C, Nardi P, Lucà G, Moroni G, Rogliani P, Perno CF, Volpi A. Clinical features and outcome of hospitalized patients with HSV-1 DNA in the lower respiratory tract. *New Microbiol*. 2017 Apr;40(2):107-112

139. Calzetta L, Puxeddu E, Rogliani P.

Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine. *EBioMedicine*. 2017 May;19:14-15

140. Cazzola M, Calzetta L, Rinaldi B, Page C, Rosano G, Rogliani P, Matera MG. Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. *Drugs*. 2017 May;77(7):721-732.

141. Liccardi G, Calzetta L, Salzillo A, Apicella G, Croce G, Rogliani P.

Can a better patients' phenotyping predict the efficacy of tiotropium in symptomatic asthma? *Allergy Asthma Proc*. 2017 May 1;38(3):19-20

142. Liccardi G, Calzetta L, Barrile A, Giorgino FM, Sapio C, Rogliani P.

Is the risk of developing atopic sensitization and bronchial asthma in animal laboratory workers preventable in well-defined susceptible individuals? *J Occup Health*. 2017 May 25;59(3):310-311

143. Braido F, Baiardini I, Alleri P, Bacci E, Barbetta C, Bellocchia M, Benfante A, Blasi F, Bucca C, Busceti MT, Centanni S, Colanardi MC, Contoli M, Corsico A, D'Amato M, Di Marco F, Marco D, Ferrari M, Florio G, Fois AG, Foschino Barbaro MP, Silvia G, Girbino G, Grosso A, Latorre M, Maniscalco S, Mazza F, Mereu C, Molinengo G, Ora J, Paggiaro P, Patella V, Pelaia G, Pirina P, Proietto A, Rogliani P, Santus P, Scichilone N, Simioli F, Solidoro P, Terraneo S, Zuccon U, Canonica GW. Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. *Pulm Pharmacol Ther*. 2017 Jun;44:83-87

144. Liccardi G, Calzetta L, Salzillo A, Piccolo A, Pane G, Rogliani P.

Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents?
Expert Opin Pharmacother. 2017 Jun;18(8):833-835

145. Cazzola M, Rogliani P, Aliberti S, Blasi F, Matera MG. An update on the pharmacotherapeutic management of lower respiratory tract infections. Expert Opin Pharmacother. 2017 Jul;18(10):973-988

146. Rogliani P, Ora J, Puxeddu E, Matera MG, Cazzola M. Adherence to COPD treatment: Myth and reality. Respir Med. 2017 Aug;129:117-123

147. Calzetta L, Ora J, Cavalli F, Rogliani P, O'Donnell DE, Cazzola M. Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. Respir Med. 2017 Aug;129:189-198

148. Calzetta L, Matera MG, Braido F, Contoli M, Corsico A, Di Marco F, Santus P, Scichilone N, Cazzola M, Rogliani P.

Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. Pulm Pharmacol Ther. 2017 Aug;45:148-158

149. Cazzola M, Calzetta L, Rogliani P, Matera MG. The Challenges of Precision Medicine in COPD. Mol Diagn Ther. 2017 Aug;21(4):345-355

150. Mantero M, Rogliani P, Di Pasquale M, Polverino E, Crisafulli E, Guerrero M, Gramegna A, Cazzola M, Blasi F. Acute exacerbations of COPD: risk factors for failure and relapse. Int J Chron Obstruct Pulmon Dis. 2017 Sep 8;12:2687-2693

151. Cazzola M, Rogliani P, Calzetta L, Lauro D, Page C, Matera MG. Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. Trends Pharmacol Sci. 2017 Oct;38(10):940-951

152. Cazzola M, Rogliani P.

Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. J Comp Eff Res. 2017 Oct;6(7):627-636

153. Cazzola M, Rogliani P.

In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV₁ than long-acting beta-agonists plus inhaled corticosteroids. *Evid Based Med.* 2017 Oct;22(5):183-184

154. Liccardi G, Caminati M, Senna G, Calzetta L, Rogliani P.

Anaphylaxis and intimate behaviour. *Curr Opin Allergy Clin Immunol.* 2017 Oct;17(5):350-355

155. Calzetta L, Rogliani P, Mattei M, Alfonsi P, Cito G, Pistocchini E, Cazzola M, Matera MG. Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. *COPD.* 2017 Oct;14(5):526-532

156. Cazzola M, Rogliani P, Calzetta L, Hanania NA, Matera MG. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. *COPD.* 2017 Oct;14(5):552-563

157. Calzetta L, Rogliani P, Facciolo F, Rendina E, Cazzola M, Matera MG. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. *Eur J Pharmacol.* 2017 Oct 5;812:147-154

158. Calzetta L, Roncada P, di Cave D, Bonizzi L, Urbani A, Pistocchini E, Rogliani P, Matera MG. Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis. *Equine Vet J.* 2017 Nov;49(6):710-717

159. Matera MG, Rogliani P, Zanasi A, Cazzola M. Bronchodilator therapy for chronic cough. *Pulm Pharmacol Ther.* 2017 Dec;47:88-92

160. Contoli M, Corsico AG, Santus P, Di Marco F, Braido F, Rogliani P, Calzetta L, Scichilone N. Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine. *COPD.* 2017 Dec;14(6):641-647

161. Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. *Int J Chron Obstruct Pulmon Dis.* 2017 Dec 5;12:3469-3485

162. Sverzellati N, Odone A, Silva M, Polverosi R, Florio C, Cardinale L, Cortese G, Addonizio G, Zompatori M, Dalpiaz G, Piciucchi S, Larici AR; Italian Structured Report on Fibrosing Lung Disease Consort. Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist. *Radiol Med*. 2017 Dec 11

163. Matera MG, Rogliani P, Calzetta L, Cazzola M. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. *Expert Opin Drug Metab Toxicol*. 2017 Dec 27:1-7

164. Rogliani P, Ora J, Puxeddu E, Calzetta L, Cavalli F, Matera MG, Cazzola M. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. *Pulm Pharmacol Ther*. 2017 Dec 30

165. Yoo DK, Zompatori M, Barrile A, Rossi G, D'Amato D, Sergiacomi G, Rogliani P, Mura M. Associated Pulmonary Hypertension Is an Independent Contributor to Exercise Intolerance in Chronic Fibrosing Interstitial Pneumonias. *Respiration*. 2018;96(6):543-551.

166. Labor M, Braido F, Bikov A, Lahousse L, Rogliani P, Baiardini I.

LABA/LAMA Fixed Dose Combination in Chronic Obstructive Pulmonary Disease: The Impact on Health-Related Quality of Life. *Respiration*. 2018;96(4):370-381.

167. Liccardi G, Calzetta L, Milanese M, Salzillo A, Apicella G, Matera MG, Rogliani P.

Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection? *J Allergy Clin Immunol Pract*. 2018 May - Jun;6(3):1093-1094.

168. Liccardi G, Calzetta L, Milanese M, Maniscalco M, Salzillo A, Rogliani P.

Indoor environmental interventions for furry pet allergens: How to decrease the degree of passive transport. *J Allergy Clin Immunol Pract*. 2018 Sep - Oct;6(5):1808-180

169. Cazzola M, Rogliani P, Puxeddu E, Ora J, Matera MG.

An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? *Expert Rev Respir Med*. 2018 Jan;12(1):43-54.

170. Cazzola M, Rogliani P, Matera MG.

Long-term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved. *Pol Arch Intern Med.* 2018 Jan 31;128(1):4-6.

171. Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG.

Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. *Pulm Pharmacol Ther.* 2018 Feb;48:185-194.

172. Liccardi G, Calzetta L, Salzillo A, Piccolo A, Apicella G, Rogliani P.

Anxiety and asthma in youth. Is a stress-induced increased cholinergic tone the possible link? *Pediatr Pulmonol.* 2018 Feb;53(2):128-129.

173. Rogliani P, Brusasco V, Fabbri L, Ungar A, Muscianisi E, Barisone I, Corsini A, De Angelis G. Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary disease. *Expert Rev Respir Med.* 2018 Feb;12(2):103-112.

174. : Matera MG, Rogliani P, Calzetta L, Cazzola M.

Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. *Expert Opin Drug Metab Toxicol.* 2018

Feb;14(2):239-245.

175. Liccardi G, Calzetta L, Baldi G, Berra A, Billeri L, Caminati M, Capano P, Carpentieri E, Ciccarelli A, Crivellaro MA, Cutajar M, D'Amato M, Folletti I, Gani F, Gargano D, Giannattasio D, Giovannini M, Lombardi C, Schiavo ML, Madonna F, Maniscalco M, Meriggi A, Micucci C, Milanese M, Montera C, Paolocci G, Parente R, Pedicini A, Pio R, Puggioni F, Russo M, Salzillo A, Scavalli P, Scichilone N, Sposato B, Stanzola A, Steinhilber G, Vatrella A, Rogliani P, Passalacqua G; Italian Allergic Respiratory Diseases Task Force. Allergic sensitization to

common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study. *Clin Mol Allergy.* 2018 Feb 2;16:3.

176. : Sverzellati N, Odone A, Silva M, Polverosi R, Florio C, Cardinale L, Cortese G, Addonizio G, Zompatori M, Dalpiaz G, Piciucchi S, Larici AR; Italian Structured Report on Fibrosing Lung Disease Consort. Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist. *Radiol Med.* 2018 Apr;123(4):245-253.

177. Rogliani P, Ora J, Puxeddu E, Calzetta L, Cavalli F, Matera MG, Cazzola M.

Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. *Pulm Pharmacol Ther.* 2018 Apr;49:20-26.

178. Calzetta L, Rogliani P, Pistocchini E, Mattei M, Cito G, Alfonsi P, Page C, Matera MG. Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue. *Pulm Pharmacol Ther.* 2018 Apr;49:88-94.

179. Calzetta L, Matera MG, Rogliani P, Cazzola M.

Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. *Expert Rev Respir Med.* 2018 Apr;12(4):261-264.

180. Cazzola M, Matera MG, Levi-Schaffer F, Rogliani P.

Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. *Expert Opin Drug Saf.* 2018 Apr;17(4):429-435.

181. Cazzola M, Calzetta L, Matera MG, Hanania NA, Rogliani P.

How does race/ethnicity influence pharmacological response to asthma therapies? *Expert Opin Drug Metab Toxicol.* 2018 Apr;14(4):435-446.

.

182. Calzetta L, Matera MG, Facciolo F, Cazzola M, Rogliani P.

Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. *Respir Res.* 2018 Apr 12;19(1):65.

183. Rogliani P, Calzetta L, Cazzola M.

Is ICS-LAMA an alternative option to treat patients with COPD? *Lancet Respir Med.* 2018 May;6(5):316-317.

184. Matera MG, Calzetta L, Puxeddu E, Rogliani P, Cazzola M.

A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. *Expert Opin Drug Saf.* 2018

May;17(5):509-517.

185. Faverio P, De Giacomi F, Sardella L, Fiorentino G, Carone M, Salerno F, Ora J, Rogliani P, Pellegrino G, Sferrazza Papa GF, Bini F, Bodini BD, Messinesi G, Pesci A, Esquinas A. Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. *BMC Pulm Med*. 2018 May 15;18(1):70.
186. Rogliani P, Matera MG, Puxeddu E, Mantero M, Blasi F, Cazzola M, Calzetta L. Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. *Pulm Pharmacol Ther*. 2018 Jun;50:28-37.
187. Rogliani P, Ora J, Matera MG, Cazzola M, Calzetta L. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. *Expert Opin Drug Saf*. 2018 Jun;17(6):589-596.
188. Rogliani P, Ora J, Di Daniele N, Lauro D. Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD. *Curr Opin Pharmacol*. 2018 Jun;40:34-38.
189. Liccardi G, Calzetta L, Milanese M, Salzillo A, Manzi F, Ferrari M, Rogliani P. Psychological Stress, Lung Function and Exacerbation Risk in COPD: Is an Increase of Cholinergic Tone a Possible Link? *COPD*. 2018 Jun;15(3):310-311.
190. Liccardi G, Calzetta L, Milanese M, Lombardi C, Savi E, Passalacqua G, Rogliani P. Critical aspects in dog allergen immunotherapy (DAI). May Component Resolved Diagnosis (CRD) play a role in predicting the efficacy? *Hum Vaccin Immunother*. 2018 Jun 3;14(6):1438-1441.
191. Cazzola M, Matera MG, Rogliani P, Calzetta L. Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach? *Expert Opin Investig Drugs*. 2018 Jul;27(7):573-581.
192. Calzetta L, Rogliani P, Facciolo F, Rinaldi B, Cazzola M, Matera MG. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. *Biomed Pharmacother*. 2018 Jul;103:1-8.
193. Cazzola M, Calzetta L, Rogliani P, Page C, Matera MG. Impact of doxofylline in COPD: A pairwise meta-analysis. *Pulm Pharmacol Ther*. 2018 Aug;51:1-9.

194. Calzetta L, Rogliani P, Pistocchini E, Mattei M, Cito G, Alfonsi P, Page C, Matera MG. Combining long-acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways. *J Vet Pharmacol Ther.* 2018 Aug;41(4):546-554.
195. Pompeo E, Rogliani P, Cristino B, Fabbi E, Dauri M, Sergiacomi G. Staged unilateral lung volume reduction surgery: from mini-invasive to minimalist treatment strategies. *J Thorac Dis.* 2018 Aug;10(Suppl 23):S2754-S2762.
196. Calzetta L, Matera MG, Rogliani P, Cazzola M. Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease. *Expert Rev Respir Med.* 2018 Aug;12(8):693-708.
197. Matera MG, Calzetta L, Gritti G, Gallo L, Perfetto B, Donnarumma G, Cazzola M, Rogliani P, Donniacuo M, Rinaldi B. Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. *Eur J Pharmacol.* 2018 Aug 5;832:114-119.
198. Mantero M, Rogliani P, Cazzola M, Blasi F, Di Pasquale M. Emerging antibacterial and antiviral drugs for treating respiratory tract infections. *Expert Opin Emerg Drugs.* 2018 Sep;23(3):185-199.
199. Calzetta L, Rogliani P, Page C, Roncada P, Pistocchini E, Soggiu A, Piras C, Urbani A, Matera MG. Clinical effect of corticosteroids in asthma-affected horses: A quantitative synthesis. *Equine Vet J.* 2018 Sep;50(5):594-601.
200. Matera MG, Rinaldi B, Page C, Rogliani P, Cazzola M. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. *Expert Opin Drug Metab Toxicol.* 2018 Oct;14(10):1101-1111.
201. Cazzola M, Rogliani P.
Tiotropium could provide benefits in the early stage of COPD, but further studies are needed. *BMJ Evid Based Med.* 2018 Oct;23(5):183-184.
202. Liccardi G, Calzetta L, Milanese M, Scaglione M, Rogliani P.
Occupational exposure to furry animals and asthma: The complex interconnection between work and everyday life. *Ann Allergy Asthma Immunol.* 2018 Oct;121(4):512-513.

203. Rogliani P, Calzetta L, Braido F, Cazzola M, Clini E, Pelaia G, Rossi A, Scichilone N, Di Marco F. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. *Int J Chron Obstruct Pulmon Dis*. 2018 Oct 4;13:3115-3130.
204. Liccardi G, Calzetta L, Salzillo A, Apicella G, Piccolo A, Di Maro E, Rogliani P.
Dog allergy: can a prevalent or exclusive sensitization to Can f 5 be considered a lucky or negative event in real life? *Eur Ann Allergy Clin Immunol*. 2018 Nov;50(6):283-285.
205. Serajeddini H, Rogliani P, Mura M. Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity. *Lung*. 2018 Dec;196(6):707-713.
206. Matera MG, Rogliani P, Ora J, Cazzola M. Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. *Expert Opin Pharmacother*. 2018 Dec;19(18):2043-2053.
207. Cazzola M, Rogliani P, Calzetta L, Matera MG. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. *Eur Respir J*. 2018 Dec 13;52(6).
208. Baiardini I, Rogliani P, Santus P, Corsico AG, Contoli M, Scichilone N, Di Marco F, Lessi P, Scognamillo C, Molinengo G, Ferri F, Patella V, Fiorentino G, Carone M, Braido F. Disease awareness in patients with COPD: measurement and extent. *Int J Chron Obstruct Pulmon Dis*. 2018 Dec 17;14:1-11.
209. Contoli M, Rogliani P, Di Marco F, Braido F, Corsico AG, Amici CA, Piro R, Sarzani R, Lessi P, Scognamillo C, Scichilone N, Santus P; SAT Study Group. Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study. *Ther Adv Respir Dis*. 2019 Jan-Dec;13:1753466619888128.
210. Corsico AG, Braido F, Contoli M, Di Marco F, Rogliani P, Scognamillo C, Olivi I, Santus P, Scichilone N, Lazzaro C. Corrigendum to "Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up" [*Respir. Med.* 153 (2019) 68-75]. *Respir Med*. 2019 Nov - Dec;160:105724

211. Rogliani P, Matera MG, Calzetta L, Hanania NA, Page C, Rossi I, Andreadi A, Galli A, Coppola A, Cazzola M, Lauro D. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. *Respir Med.* 2019 Jul - Aug;154:86-92.
212. Sposato B, Scalese M, Milanese M, Masieri S, Cavaliere C, Latorre M, Scichilone N, Ricci A, Cresti A, Santus P, Olivieri C, Perrella A, Rogliani P, Paggiaro P; Omalizumab Italian Study Group. Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes. *J Allergy Clin Immunol Pract.* 2019 May - Jun;7(5):1643-1646.
213. Liccardi G, Calzetta L, Milanese M, Bilò MB, Rogliani P. Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice? *Int Arch Allergy Immunol.* 2019;180(2):142-143.
214. Liccardi G, Calzetta L, Apicella G, Baldi G, Berra A, Califano F, Ciccarelli A, Cutajar M, D'Amato M, De Crescenzo G, Di Maro E, Gargano D, Giannattasio D, Inciso G, Lo Schiavo M, Madonna F, Maniscalco M, Montera C, Papa G, Pedicini A, Pio R, Salzillo A, Stanziola A, Rogliani P, Musarra A. Allergy in adolescent population (14-18 years) living in Campania region (Southern Italy). A multicenter study. *Eur Ann Allergy Clin Immunol.* 2019 Jan;51(1).
215. Harari S, Caminati A, Confalonieri M, Poletti V, Vancheri C, Pesci A, Rogliani P, Luppi F, Agostini C, Rottoli P, Sanduzzi Zamparelli A, Sebastiani A, Della Porta R, Salton F, Messori B, Tomassetti S, Rosso R, Biffi A, Puxeddu E, Cerri S, Cinetto F, Refini RM, Bocchino M, Di Michele L, Specchia C, Albera C; ILDINET (Interstitial Lung Diseases Italian Network). The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone. *Clin Respir J.* 2019 Mar;13(3):166-173.
216. Liccardi G, Calzetta L, Milanese M, Passalacqua G, Rogliani P.
Can f 5 as a suitable marker of dog allergy: Assess male dog exposure before banning it. *J Allergy Clin Immunol.* 2019 Apr;143(4):1657-1658.
217. Rogliani P, Calzetta L, Matera MG, di Daniele N, Girolami A, Cazzola M, Ora J. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2019 Apr;20(6):737-750.
- 218- Calzetta L, Cazzola M, Matera MG, Rogliani P.
Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD. *Chest.* 2019

Apr;155(4):758-770.

219. Cazzola M, Rogliani P, Calzetta L, Matera MG. Bronchodilators in subjects with asthma-related comorbidities. *Respir Med.* 2019 May;151:43-48.

220. Pompeo E, Rogliani P, Atinkaya C, Guerrera F, Ruffini E, Iñiguez-Garcia MA, Peer M, Voltolini L, Caviezel C, Weder W, Opitz I, Cavalli F, Sorge R; ESTS awake thoracic surgery working group. Nonintubated surgical biopsy of undetermined interstitial lung disease: a multicentre outcome analysis. *Interact Cardiovasc Thorac Surg.* 2019 May 1;28(5):744-750.

221. Calzetta L, Cazzola M, Matera MG, Rogliani P. Response. *Chest.* 2019 May;155(5):1079-1080.

222. Rogliani P, Cazzola M, Calzetta L. Cardiovascular Disease in Chronic Respiratory Disorders and Beyond. *J Am Coll Cardiol.* 2019 May 7;73(17):2178-2180.

223. Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. *Respir Res.* 2019 May 27;20(1):104.

224. Calzetta L, Rogliani P, Page C, Rinaldi B, Cazzola M, Matera MG. Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. *Pulm Pharmacol Ther.* 2019 Jun;56:39-50.

225. Calzetta L, Matera MG, Rogliani P. Monoclonal antibodies in severe asthma: is it worth it? *Expert Opin Drug Metab Toxicol.* 2019 Jun;15(6):517-520.

226. Ricci F, Pugliese L, Cavallo AU, Forcina M, De Stasio V, Presicce M, Di Tosto F, Di Donna C, Spiritiglozzi L, Rogliani P, Floris R, Chiocchi M. Highlights of high-resolution computed tomography imaging in evaluation of complications and co-morbidities in idiopathic pulmonary fibrosis. *Acta Radiol.* 2019 Jun 25:284185119857435.

227. Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG. Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. *Trends Pharmacol Sci.* 2019 Jul;40(7):452-463.
228. Matera MG, Calzetta L, Rogliani P, Cazzola M. Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. *Respir Med.* 2019 Jul;153:3-13.
229. Corsico AG, Braido F, Contoli M, Di Marco F, Rogliani P, Scognamillo C, Olivi I, Santus P, Scichilone N, Lazzaro C. Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up. *Respir Med.* 2019 Jul;153:68-75.
230. Radovanovic D, Contoli M, Marco FD, Sotgiu G, Pelaia G, Braido F, Corsico AG, Micheletto C, Rogliani P, Scichilone N, Saderi L, Santus P, Solidoro P. Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study. *COPD.* 2019 Aug;16(3-4):215-226.
231. Rogliani P, Calzetta L, Ora J, Cazzola M, Matera MG. Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. *Multidiscip Respir Med.* 2019 Aug 3;14:25.
232. Cazzola M, Rogliani P, Stolz D, Matera MG. Pharmacological treatment and current controversies in COPD. *F1000Res.* 2019 Aug 29;8. pii: F1000 Faculty Rev-1533.
233. Cazzola M, Rogliani P, Matera MG. Ultra-LABAs for the treatment of asthma, *Respir Med.* 2019 Sep;156:47-52.
234. Vancheri C, Sebastiani A, Tomassetti S, Pesci A, Rogliani P, Tavanti L, Luppi F, Harari S, Rottoli P, Ghirardini A, Kirchgaessler KU, Albera C. Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. *Respir Med.* 2019 Sep;156:78-84.
235. Matera MG, Rinaldi B, Calzetta L, Rogliani P, Cazzola M. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. *Pulm Pharmacol Ther.* 2019 Oct;58:101828.
236. Cazzola M, Puxeddu E, Ora J, Rogliani P.

Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. *Mol Diagn Ther.* 2019 Oct;23(5):603-614.

237. Cazzola M, Calzetta L, Rogliani P, Matera MG. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. *Expert Opin Investig Drugs.* 2019 Oct;28(10):827-833.

238. Cefalo M, Puxeddu E, Sarmati L, Paterno G, Fontana C, Nasso D, Pane G, De Bellis E, Palmieri R, Buzzati E, Meconi F, Laureana R, Casciani P, Zizzari AG, Rogliani P, de Fabritiis P, Maurillo L, Buccisano F, Cantonetti M, Arcese W, Venditti A, Del Principe MI. Diagnostic Performance and Safety of Bronchoalveolar Lavage in Thrombocytopenic Haematological Patients for Invasive Fungal Infections Diagnosis: A Monocentric, Retrospective Experience. *Mediterr J Hematol Infect Dis.* 2019 Nov 1;11(1):e2019065.

239. Cazzola M, Puxeddu E, Matera MG, Rogliani P.

A potential role of triple therapy for asthma patients. *Expert Rev Respir Med.* 2019 Nov;13(11):1079-1085.

240. Principe S, Benfante A, Calzetta L, Rogliani P, Scichilone N. Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics. *World Allergy Organ J.* 2019 Nov 6;12(11):100081.

241. Colombo D, Zagni E, Ferri F, Canonica GW; PROXIMA study centers. Gender differences in asthma perception and its impact on quality of life: a post hoc analysis of the PROXIMA (Patient Reported Outcomes and Xolair(®) In the Management of Asthma) study. *Allergy Asthma Clin Immunol.* 2019 Nov 6;15:65.

242. Rogliani P, Matera MG, Ritondo BL, De Guido I, Puxeddu E, Cazzola M, Calzetta L. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. *Pulm Pharmacol Ther.* 2019 Dec;59:101841.

243. Calzetta L, Di Marco F, Blasi F, Cazzola M, Centanni S, Micheletto C, Rossi A, Rogliani P.

Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. *Pulm Pharmacol Ther.* 2019 Dec;59:101855.

244. Liccardi G, Calzetta L, Milanese M, Bilò MB, Rogliani P.

Why Are Allergens Not Detected in the Bronchoalveolar Lavage Fluid of Patients Undergoing Fiberoptic

Bronchoscopy? Possible Explanations. *J Investig Allergol Clin Immunol.* 2019 Dec;29(6):472-473.

245. Puxeddu E, Fraboni D, Cillis G, Cavalli F, Buccisano F, Rogliani P.

CD71(-) Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders

of the Disease. *Am J Respir Crit Care Med.* 2019 Dec 1;200(11):1444-1446.

246. Calzetta L, Matera MG, Cazzola M, Rogliani P.

Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to

Patients. *Adv Ther.* 2019 Dec;36(12):3291-3298.

247. Cazzola M, Rogliani P, Matera MG. The future of bronchodilation: looking for new classes of bronchodilators. *Eur Respir Rev.* 2019 Dec 23;28(154).

248. Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M.

Pharmacology and Therapeutics of Bronchodilators Revisited. *Pharmacol Rev.* 2020 Jan;72(1):218-252.

249. Principe S, Benfante A, Calzetta L, Rogliani P, Scichilone N.

Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics. *World Allergy Organ J.* 2019 Nov 6;12(11):100081.

250. Sposato B, Camiciottoli G, Bacci E, Scalese M, Carpagnano GE, Pelaia C, Santus P, Maniscalco M, Masieri S, Corsico A, Scichilone N, Baglioni S, Murgia N, Folletti I, Bardi G, Grosso A, Cameli P, Latorre M, Musarra A, Bargagli E, Ricci A, Pelaia G, Paggiaro P, Rogliani P. Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life. *Pulm Pharmacol Ther.* 2020 Apr;61:101899.

251. Cazzola M, Calzetta L, Rogliani P, Matera MG.

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β -Agonists in COPD: Accumulating Evidence from Network Meta-Analyses. *Pulm Ther.* 2019 Dec;5(2):117-126.

252. Ricci F, Pugliese L, Cavallo AU, Forcina M, De Stasio V, Presicce M, Di Tosto F, Di Donna C, Spiritiglozzi L, Rogliani P, Floris R, Chiocchi M. Highlights of high-resolution computed tomography imaging in evaluation of complications and co-morbidities in idiopathic pulmonary fibrosis. *Acta Radiol.* 2020 Feb;61(2):204-218.

253. Rogliani P, Sforza M, Calzetta L. The impact of comorbidities on severe asthma.

Curr Opin Pulm Med. 2020 Jan;26(1):47-55.

254. Rogliani P, Matera MG, Facciolo F, Page C, Cazzola M, Calzetta L

Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo. *Br J Pharmacol.* 2020 Mar;177(5):1150-1163.

255. Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M.

Pharmacology and Therapeutics of Bronchodilators Revisited. *Pharmacol Rev.* 2020 Jan;72(1):218-252.

256. Calzetta L, Matera MG, Goldstein MF, Fairweather WR, Howard WW, Cazzola M, Rogliani P.

A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study. *Pulm Pharmacol Ther.* 2020 Feb;60:101883.

257. Sposato B, Camiciottoli G, Bacci E, Scalese M, Carpagnano GE, Pelaia C, Santus P, Maniscalco M, Masieri S, Corsico A, Scichilone N, Baglioni S, Murgia N, Folletti I, Bardi G, Grosso A, Cameli P, Latorre M, Musarra A, Bargagli E, Ricci A, Pelaia G, Paggiaro P, Rogliani P. Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life. *Pulm Pharmacol Ther.* 2020 Apr;61:101899.

258. Rogliani P, Calzetta L, Matera MG, Laitano R, Ritondo BL, Hanania NA, Cazzola M. Severe Asthma and Biological Therapy: When, Which, and for Whom. *Pulm Ther.* 2020 Jun;6(1):47-66.

259. Cazzola M, Stolz D, Rogliani P, Matera MG.

α 1-Antitrypsin deficiency and chronic respiratory disorders. *Eur Respir Rev.* 2020 Feb 12;29(155):190073.

260. Matera MG, Rogliani P, Calzetta L, Cazzola M. TSLP Inhibitors for Asthma: Current Status and Future Prospects.

Drugs. 2020 Apr;80(5):449-458.

261. Cazzola M, Cavalli F, Usmani OS, Rogliani P.

Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. *Expert Opin Drug Deliv.* 2020 May;17(5):635-646.

262. Canonica GW, Colombo GL, Rogliani P, Santus P, Pitotti C, Di Matteo S, Martinotti C, Bruno GM. Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study. *Risk Manag Healthc*

Policy. 2020 Jan 22;13:43-53.

263. Calzetta L, Ritondo BL, Matera MG, Cazzola M, Rogliani P.

Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. *Expert Rev Respir Med.* 2020 Jun;14(6):621-635.

264. Liccardi G, Calzetta L, Bilò MB, Brusca I, Cecchi L, Costantino MT, Da Re M, Buzzulini F, Giani M, Lombardi C, Meneguzzi G, Meriggi A, Milanese M, Onida R, Patella V, Pignatti P, Quercia O, Ridolo E, Sabatino G, Sacerdoti C, Savi E, Scala E, Steinhilber G, Villalta D, Passalacqua G, Rogliani P; Italian Allergic Respiratory Diseases Task Force.

A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study. *J Allergy Clin Immunol Pract.* 2020 Jul-Aug;8(7):2399-2401.

265. Lavorini F, Bianco A, Blasi F, Braidò F, Corsico AG, Di Marco F, Gentile A, Paggiaro PL, Pegoraro V, Pelaia G, Rogliani P, Santus P, Scichilone N, Soldi A, Canonica GW. What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis. *Respir Med.* 2020 May;166:105937.

266. Rogliani P, Ritondo BL, Zerillo B, Cazzola M, Matera MG, Calzetta L. Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination. *COPD*. 2020 Apr;17(2):215-223.

267. Liccardi G, Calzetta L, Milanese M, Bilò MB, Liccardi MV, Matera MG, Rogliani P.

Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control? *Monaldi Arch Chest Dis*. 2020 Apr 8;90(1).

268. Liccardi G, Calzetta L, Milanese M, Bilò MB, Liccardi MV, Matera MG, Baiardini I, Rogliani P.

Anxiety/depression and impaired asthma control in adolescents. Is an increased basal cholinergic tone a possible link ?

Eur Ann Allergy Clin Immunol. 2020 Jul;52(4):190-192.

269. Liccardi G, Calzetta L, Berra A, Caiazzo R, Califano F, Ciccarelli A, Cutajar M, D'Amato M, De Bartolomeis F, Dello Iacono I, Gargano D, Lo Schiavo M, Madonna F, Maniscalco M, Milanese M, Montera C, Narducci R, Papa G, Pedicini A, Sabatino G, Sacerdoti C, Savoia A, Stanziola A, Bilò MB, Rogliani P.

Unmet needs and relationship between general practitioners (GPs) and allergists living in Campania region (southern Italy). *Eur Ann Allergy Clin Immunol*. 2020 Sep;52(5):230-234.

270. Calzetta L, Ritondo BL, Matera MG, Pezzuto G, Cazzola M, Rogliani P.

Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD). *Expert Opin Investig Drugs*. 2020 Jul;29(7):723-738.

271. Liguori C, Pierantozzi M, Spanetta M, Sarmati L, Cesta N, Iannetta M, Ora J, Mina GG, Puxeddu E, Balbi O, Pezzuto G, Magrini A, Rogliani P, Andreoni M, Mercuri NB. Subjective neurological symptoms frequently occur in patients with

SARS-CoV2 infection. *Brain Behav Immun*. 2020 Aug;88:11-16.

272. Rogliani P, Ritondo BL, Ora J, Cazzola M, Calzetta L.

SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. *Eur Respir J*. 2020 Sep 10;56(3):2000625.

273. Elkhoully AG, Sorge R, Rogliani P, Cristino B, Wahby E, Serag A, Liang H, He J, Pompeo E.

Ergonomical Assessment of Three-Dimensional Versus Two-Dimensional Thoracoscopic Lobectomy. *Semin Thorac Cardiovasc Surg.* 2020 Winter;32(4):1089-1096.

274. Ora J, Puxeddu E, Cavalli F, Giorgino FM, Girolami A, Chiocchi M, Sergiacomi G, Federici M, Rogliani P.

Does bronchoscopy help the diagnosis in COVID-19 infection? *Eur Respir J.* 2020 Aug 6;56(2):2001619.

275. Sposato B, Scalese M, Rogliani P.

Seasonal monitoring of serum IgE and blood eosinophil variability may lead to a better severe asthma phenotyping and to a

correct biologic prescription. *J Biol Regul Homeost Agents.* 2020 Jan- Feb;34(1):315-318.

276. Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P; ETHOS Investigators. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. *N Engl J Med.* 2020 Jul 2;383(1):35-48.

277. Calzetta L, Matera MG, Rogliani P, Cazzola M. The role of triple therapy in the management of COPD. *Expert Rev Clin Pharmacol.* 2020 Aug;13(8):865-874.

278. Cazzola M, Rogliani P, Matera MG.

The latest on the role of LAMAs in asthma. *J Allergy Clin Immunol.* 2020 Dec;146(6):1288-1291.

279. Braghiroli A, Braido F, Piraino A, Rogliani P, Santus P, Scichilone N. Day and Night Control of COPD and Role of Pharmacotherapy: A Review. *Int J Chron Obstruct Pulmon Dis.* 2020 Jun 4;15:1269-1285.

280. Scichilone N, Barnes PJ, Battaglia S, Benfante A, Brown R, Canonica GW, Caramori G, Cazzola M, Centanni S, Cianferoni A, Corsico A, De Carlo G, Di Marco F, Gaga M, Hawrylowicz C, Heffler E, Matera MG, Matucci A, Paggiaro P, Papi A, Popov T, Rogliani P, Santus P, Solidoro P, Toghias A, Boulet LP. The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. *J Clin Med.* 2020 Jul 27;9(8):2397.

281. Ora J, Liguori C, Puxeddu E, Coppola A, Matino M, Pierantozzi M, Mercuri NB, Rogliani P. Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. *Neurol Sci.* 2020 Oct;41(10):2671-2674.
282. Matera MG, Rogliani P, Bianco A, Cazzola M. Pharmacological management of adult patients with acute respiratory distress syndrome. *Expert Opin Pharmacother.* 2020 Dec;21(17):2169-2183.
283. Matera MG, Rogliani P, Calzetta L, Cazzola M. Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. *Respir Med.* 2020 Sep;171:106114.
284. Cazzola M, Rogliani P, Calzetta L, Matera MG. Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy. *Pharmgenomics Pers Med.* 2020 Aug 4;13:261-271.
285. Ora J, Calzetta L, Matera MG, Cazzola M, Rogliani P. Advances with glucocorticoids in the treatment of asthma: state of the art. *Expert Opin Pharmacother.* 2020 Dec;21(18):2305-2316.
286. Novelli A, Andreani M, Biancolella M, Liberatoscioli L, Passarelli C, Colona VL, Rogliani P, Leonardis F, Campana A, Carsetti R, Andreoni M, Bernardini S, Novelli G, Locatelli F. HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients. *HLA.* 2020 Nov;96(5):610-614.
287. Liguori C, Spanetta M, Sarmati L, Cesta N, Pezzuto G, Mina GG, Rogliani P, Pierantozzi M. Sleep and wake impairment in patients with SARS-CoV2 infection. *Sleep Med.* 2020 Sep;73:177-178.
288. Calzetta L, Ritondo BL, de Marco P, Cazzola M, Rogliani P. Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. *Expert Rev Respir Med.* 2021 Jan;15(1):143-152.

289. Calzetta L, Ritondo BL, Matera MG, Facciolo F, Rogliani P.

Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab.

Br J Pharmacol. 2020 Oct;177(20):4750-4765.

290. Latini A, Agolini E, Novelli A, Borgiani P, Giannini R, Gravina P, Smarrazzo A, Dauri M, Andreoni M, Rogliani P, Bernardini S, Helmer-Citterich M, Biancolella M, Novelli G. COVID-19 and Genetic Variants of Protein Involved in

the SARS-CoV-2 Entry into the Host Cells. Genes (Basel). 2020 Aug 27;11(9):1010.

291. Rogliani P, Ritondo BL, Gabriele M, Cazzola M, Calzetta L. Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings. Expert Rev Clin Pharmacol. 2020 Sep;13(9):977-990.

292. Novelli A, Biancolella M, Borgiani P, Cocciadiferro D, Colona VL, D'Apice MR, Rogliani P, Zaffina S, Leonardis F, Campana A, Raponi M, Andreoni M, Grelli S, Novelli G. Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients. Hum Genomics. 2020 Sep 11;14(1):29.

293. Rogliani P, Ritondo BL, Puxeddu E, Pane G, Cazzola M, Calzetta L. Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review. J Exp Pharmacol. 2020 Aug 6;12:233-254.

294. Amati F, Vancheri C, Latini A, Colona VL, Grelli S, D'Apice MR, Balestrieri E, Passarelli C, Minutolo A, Loddo S, Di Lorenzo A, Rogliani P, Andreoni M, Novelli G. Expression profiles of the SARS-CoV-2 host invasion genes in nasopharyngeal and oropharyngeal swabs of COVID-19 patients. Heliyon. 2020 Oct;6(10):e05143.

295. Sposato B, Scalese M, Camiciottoli G, Carpagnano GE, Pelaia C, Santus P, Maniscalco M, Corsico A, Grosso A, Baglioni S, Murgia N, Folletti I, Pelaia G, Masieri S, Cavaliere C, Musarra A, Bargagli E, Ricci A, Latorre M, Paggiaro P, Rogliani P. Mepolizumab Effectiveness and Allergic Status in Real Life. Int Arch Allergy Immunol. 2020 Oct 28:1-8.

296. Rogliani P, Calzetta L, Coppola A, Puxeddu E, Sergiacomi G, D'Amato D, Orlicchio A.

Are there pulmonary sequelae in patients recovering from COVID-19? *Respir Res.* 2020 Oct 30;21(1):286.

297. Ritondo BL, Puxeddu E, Calzetta L, Cazzola M, Rogliani P.

Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. *Expert Opin Pharmacother.* 2020 Nov 11:1-10.

298. Cazzola M, Page C, Rogliani P, Calzetta L, Matera MG. Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent. *Drugs.* 2020 Nov;80(17):1799-1809.

299. Sposato B, Scalese M, Camiciottoli G, Carpagnano GE, Pelaia C, Santus P, Maniscalco M, Corsico A, Grosso A, Baglioni S, Murgia N, Folletti I, Pelaia G, Masieri S, Cavaliere C, Musarra A, Bargagli E, Ricci A, Latorre M, Rogliani P, Paggiaro P. Real-life Mepolizumab effectiveness in severe eosinophilic asthmatics with nasal polyposis. *Respir Med Res.* 2020 Nov;78:100791.

300. Calzetta L, Matera MG, Coppola A, Rogliani P.

Prospects for severe asthma treatment. *Curr Opin Pharmacol.* 2020 Dec 10;56:52-60.

301. Rogliani P, Lauro D, Di Daniele N, Chetta A, Calzetta L.

Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?

Expert Rev Respir Med. 2020 Dec 3:1-8.

302. Papi A, Avdeev S, Calverley PMA, Cordeiro CR, Jesenak M, Koblížek V, Petkova D, Rogliani P, Tarraf H, Tzanakis N, Ulmeanu R, Uzaslan E, Adir Y. Use of mucolytics in COPD: A Delphi consensus study. *Respir Med.* 2020 Dec;175:106190.

303. Ora J, Coppola A, Cazzola M, Calzetta L, Rogliani P.

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease.

J Exp Pharmacol. 2020 Dec 8;12:559-574.

304. Matteucci C, Minutolo A, Balestrieri E, Petrone V, Fanelli M, Malagnino V, Ianetta M, Giovinazzo A, Barreca F, Di Cesare S, De Marco P, Miele MT, Toschi N, Mastino A, Sinibaldi

Vallebona P, Bernardini S, Rogliani P, Sarmati L, Andreoni M, Grelli S, Garaci E. Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. *Open Forum Infect Dis.* 2020 Dec 5;8(1):ofaa588.

305. Calzetta L, Ludovica Ritondo B, de Marco P, Cazzola M, Rogliani P.

Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile. *Expert Rev Respir Med.* 2020 Dec 28:1-3.

306. Rogliani P, Ritondo BL, Laitano R, Chetta A, Calzetta L. Advances in understanding of mechanisms related to increased cardiovascular risk in COPD. *Expert Rev Respir Med.* 2021 Jan;15(1):59-70.

307. Liguori C, Pierantozzi M, Spanetta M, Sarmati L, Cesta N, Iannetta M, Ora J, Mina GG, Puxeddu E, Balbi O, Pezzuto G, Magrini A, Rogliani P, Andreoni M, Mercuri NB. Depressive and anxiety symptoms in patients with SARS-CoV2 infection. *J Affect Disord.* 2021 Jan 1;278:339-340.

308 Cazzola M, Ora J, Bianco A, Rogliani P, Matera MG. Guidance on nebulization during the current COVID-19 pandemic. *Respir Med.* 2021 Jan;176:106236.

309. Calverley P, Rogliani P, Papi A.

Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. *Drug Saf.* 2021 Mar;44(3):273-290.

310. Sposato B, Scalese M, Ricci A, Rogliani P, Paggiaro P; Omalizumab Italian Study Group. Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma.

Clin Respir J. 2021 Feb;15(2):237-243.

311. Ora J, Rogliani P, Dauri M, O'Donnell D. Happy hypoxemia, or blunted ventilation? *Respir Res.* 2021 Jan 6;22(1):4.

312. Matera MG, Calzetta L, Ora J, Rogliani P, Cazzola M. Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. *Expert Opin Drug Deliv.* 2021 Jan 19:1-16.

313. Rogliani P, Calzetta L. Mortality in ETHOS, a Question of "Power".

Am J Respir Crit Care Med. 2021 Jan 14.

314. Rogliani P, Ritondo BL, Cavalli F, Giorgino F, Girolami A, Pane G, Pezzuto G, Zerillo B, Puxeddu E, Ora J. Synergy across the drugs approved for the treatment of asthma. *Minerva Med.* 2021 Jan 26.

315. Rogliani P, Ritondo BL, Calzetta L.

Triple therapy in uncontrolled asthma: a network meta-analysis of Phase III studies. *Eur Respir J.* 2021 Jan 28:2004233.

316. Matteucci A, Massaro G, Sergi D, Bonanni M, Stifano G, Matino M, Zerillo B, Rogliani P, Romeo F.

Electrocardiographic modifications and cardiac involvement in COVID-19 patients: results from an Italian cohort.

J Cardiovasc Med (Hagerstown). 2021 Mar 1;22(3):190-196.

317. Matera MG, Ora J, Calzetta L, Rogliani P, Cazzola M. Sex differences in COPD management.

Expert Rev Clin Pharmacol. 2021 Feb 9.

318. Papi A, Fabbri LM, Kerstjens HAM, Rogliani P, Watz H, Singh D. Inhaled long- acting muscarinic antagonists in asthma - A narrative review. *Eur J Intern Med.* 2021 Feb 6:S0953-6205(21)00033-9.

319. Cazzola M, Ora J, Cavalli F, Rogliani P, Matera MG.

Treatable Mechanisms in Asthma. *Mol Diagn Ther.* 2021 Feb 11.

320. Cazzola M, Matera MG, Rogliani P, Calzetta L. Comparative studies of dual bronchodilation in COPD. *Monaldi Arch Chest Dis.* 2021 Feb 12;91(1).

321. Calzetta L, Coppola A, Ritondo BL, Matino M, Chetta A, Rogliani P.

The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review. *Int J Chron Obstruct Pulmon Dis*. 2021 Feb 12;16:257-279.

322 Rogliani P, Calzetta L.

Response to letter to the editor. Again on IMPACT: exacerbation after abrupt discontinuation of ICS and pneumonia in fluticasone furoate-containing FDCs. *Expert Opin Pharmacother*. 2021 May;22(7):943-945.

323 Baiardini I, Contoli M, Corsico AG, Scognamillo C, Ferri F, Scichilone N, Rogliani P, Di Marco F, Santus P, Braido F.

Exploring the Relationship between Disease Awareness and Outcomes in Patients with Chronic Obstructive Pulmonary Disease. *Respiration*. 2021;100(4):291-297.

324 Liccardi G, Calzetta L, Milanese M, Bilò MB, Liccardi MV, Baiardini I, Gargano D, Lo Schiavo M, Madonna F, Montera MC, Papa A, Pedicini A, Habetswallner F, Giordano A, Rogliani P.

Can placebo challenge test (inducing a "nocebo effect") be a suitable model to assess stress-induced bronchial obstruction? Suggestions from the multidisciplinary Working Groups "Stress-Asthma" and "AAIITO Regione Campania". *Eur Ann Allergy Clin Immunol*. 2021 Mar 16

325 Matera MG, Ora J, Cavalli F, Rogliani P, Cazzola M.

New Avenues for Phosphodiesterase Inhibitors in Asthma. *J Exp Pharmacol*. 2021 Mar 15;13:291-302.

326 Rogliani P, Chetta A, Cazzola M, Calzetta L

SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. *Vaccines (Basel)*. 2021 Mar 5;9(3):227.

327 Pompeo E, Elkhoully A, Rogliani P, Dauri M, Peer M, Sergiacomi G, Sorge R.

Quasibar minimal lung volume reduction surgery. *Eur J Cardiothorac Surg*. 2021 Apr 16:ezab174.

328 Calzetta L, Ritondo BL, Coppola A, Matera MG, Di Daniele N, Rogliani P

Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials. *Vaccines (Basel)*. 2021 Apr 1;9(4):341.

329 Calzetta L, Aiello M, Frizzelli A, Rogliani P, Chetta A.

Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom.

J Clin Med. 2021 Apr 10;10(8):1607

330 Liccardi G, Milanese M, Bilò MB, Liccardi MV, Gargano D, Giordano A, Habetswallner F, Lo Schiavo M, Madonna F, Montera MC, Pane G, Papa A, Pedicini A, Rogliani P.

Lessons from peculiar cases of anaphylaxis: why allergists should be prepared for the unexpected.

Eur Ann Allergy Clin Immunol. 2021 May 3.

331 Cazzola M, Ora J, Bianco A, Rogliani P, Matera MG.

Management of COPD patients during COVID: difficulties and experiences.

Expert Rev Respir Med. 2021 May 19:1-9.

332 Cazzola M, Matera MG, Rogliani P, Calzetta L, Ora J.

Step-up and step-down approaches in the treatment of asthma.

Expert Rev Respir Med. 2021 Jun 7:1-10.

333 Tacconi F, Rogliani P, Leonardis F, Sarmati L, Fabbi E, De Carolis G, La Rocca E, Vanni G, Ambrogi V.

Incidence of pneumomediastinum in COVID-19: A single-center comparison between 1st and 2nd wave.

Respir Investig. 2021 May 28:S2212-5345(21)00080-0

334 Rogliani P, Ora J, Girolami A, Rossi I, de Guido I, Facciolo F, Cazzola M, Calzetta L.

Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study.

Pulm Pharmacol Ther. 2021 Jun 12;69:102050

335 Sansone VA, Proserpio P, Mauro L, Biost AL, Frezza E, Lanza A, Rogliani P, Pezzuto G, Falcier E, Aggradi CF, Pirola A, Rao F, Roma E, Galluzzi C, Spanetta M, Cattaneo F, Rubino A, Agostoni EC, Amico F, Zanolini A, Izzi F, Greco G, Romigi A, Liguori C, Nobili L, Placidi F, Massa R.

Assessment of self-reported and objective daytime sleepiness in adult-onset myotonic dystrophy type 1.

J Clin Sleep Med. 2021 Jun 22.

336 Calzetta L, Ritondo BL, Matera MG, Chetta A, Rogliani P.

Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies.

Expert Rev Respir Med. 2021 Jul 1.

337 Ora J, Calzetta L, Ritondo BL, Matera MG, Rogliani P.

Current long-acting muscarinic antagonists for the treatment of asthma.

Expert Opin Pharmacother. 2021 Jul 3.

338 Bellia A, Andreadi A, Giudice L, De Taddeo S, Maiorino A, D'Ippolito I, Giorgino FM, Ruotolo V, Romano M, Magrini A, Di Daniele N, Rogliani P, Lauro D.

Atherogenic Dyslipidemia on Admission Is Associated With Poorer Outcome in People With and Without Diabetes Hospitalized for COVID-19.

Diabetes Care. 2021 Jul 12:dc202838. doi: 10.2337/dc20-2838.

339 Sposato B, Petrucci E, Lacerenza GL, Micheletto C, Montagnani A, Alessandri M, Cresti A, Serafini A, Lena F, Scala R, Rogliani P, Perrella A, Scalese M.

Sex differences in excessive oral corticosteroid exposure in poor adherent adult asthmatics overusing short-acting β -2 agonists.

Minerva Med. 2021 Jul 16.

340 Calzetta L, Aiello M, Frizzelli A, Bertorelli G, Rogliani P, Chetta A.

Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence.

Int J Mol Sci. 2021 Jul 1;22(13):7132.

341 Cazzola M, Matera MG, Calzetta L, Rogliani P.

Editorial overview: Respiratory: Pulmonary pharmacology-The emergence of new treatments in pulmonary medicine is finally providing real therapeutic perspectives.

Curr Opin Pharmacol. 2021 Oct;60:54-58.

342 Ora J, Prendi E, Ritondo BL, Pata X, Spada F, Rogliani P.

Pulmonary Rehabilitation in Noncystic Fibrosis Bronchiectasis.

Respiration. 2021 Aug 5:1-9.

343 Rogliani P, Ritondo BL, Facciolo F, Matera MG, Nikolaev I, Calzetta L.

Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways.

Pharmacol Res. 2021 Oct;172:105801.

344 Cazzola M, Rogliani P, Mazzeo F, Matera MG

Controversy surrounding the Sputnik V vaccine.

Respir Med. 2021 Oct;187:106569.

345 Cazzola M, Rogliani P, Salvi SS, Ora J, Matera MG.

Use of Thiols in the Treatment of COVID-19: Current Evidence.

Lung. 2021 Aug;199(4):335-343.

346 Liccardi G, Bilo MB, Milanese M, Martini M, Calzetta L, Califano F, Carucci L, Ciccarelli A, Cutajar M, D'Auria P, De Bartolomeis F, Dello Iacono I, Franzese A, Gargano D, Inciso G, Giordano AC, Iannaccone R, Lo Schiavo M, Nappi L, Madonna F, Montera C, Onorati G, Papa A, Pedicini A, Sabatino G, Sacerdoti C, Savoia A, Scopano E, Iannotta MP, Bartiromo M, Del Monaco G, Rogliani P.

Face masks during COVID-19 pandemic lockdown and self-reported seasonal allergic rhinitis symptoms.

Rhinology. 2021 Oct 1;59(5):481-484.

347 Cazzola M, Ora J, Cavalli F, Rogliani P, Matera MG.

An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease.

Biologics. 2021 Aug 27;15:363-374.

348 Calzetta L, Pietroiusti A, Page C, Bussolati O, Chetta A, Facciolo F, Rogliani P.

Multi-walled carbon nanotubes induce airway hyperresponsiveness in human bronchi by stimulating sensory C-fibers and increasing the release of neuronal acetylcholine.

Expert Rev Respir Med. 2021 Nov;15(11):1473-1481.

349 Sposato B, Petrucci E, Serafini A, Lena F, Lacerenza LG, Montagnani A, Alessandri M, Cresti A, Scala R, Rogliani P, Ricci A, Perrella A, Scalese M.

Which LABA/LAMA should be chosen in COPD patients in real life?

Pulm Pharmacol Ther. 2021 Sep 13;71:102076

350 Rogliani P, Beasley R, Cazzola M, Calzetta L.

SMART for the treatment of asthma: A network meta-analysis of real-world evidence.

Respir Med. 2021 Nov;188:106611.

351 Calzetta L, Aiello M, Frizzelli A, Bertorelli G, Ritondo BL, Rogliani P, Chetta A.

The Impact of Monoclonal Antibodies on Airway Smooth Muscle Contractility in Asthma: A Systematic Review.

Biomedicines. 2021 Sep 21;9(9):1281.

352 Rogliani P, Ritondo BL, Puxeddu E, Cazzola M, Calzetta L.

Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review.

Respir Med. 2021 Oct 5;189:106639.

CONTRIBUTION IN VOLUME (CHAPTER OR ESSAY)

- Frasca L, Ambrogi V, Rogliani P, Saltini C and Pompeo E (2012).

Awake Lung Biopsy for Interstitial Lung Disease . Chapter In, "Awake Thoracic Surgery". p. 105-118 , London: Bentham Ebooks, ISBN: 978-1-60805-288-2

- Rogliani P, Ciaprini C (2013).

IL PAZIENTE FUMATORE. In: Breviario Medico. Pavia: Selecta Medica

- Rogliani P, Segreti A, Cazzola M (2014).

Chapter:15. Adult Cardiac Conditions . In: Richard F. Lockey, MD, Dennis K. Ledford, MD, and With WAO . (a cura di): OXFORD PRESS, Asthma. Comorbidities, Coexisting Conditions, and Differential Diagnosis.


- Mario Cazzola and Paola Rogliani (2015)

"Inhaled medication: which device for which patient?", in "Controversies in COPD", Edited by Antonio Anzueto, Yvonne Heijdra and John R. Hurst. ERS Monograph, Septmeber 2015

- Paola Rogliani and Luigino Calzetta (2020)

"Cardiovascular disease in chronic obstructive pulmonary disease" in "Cardiovascular Implications of Respiratory Disorders" Edited by Miguel Ángel Martínez-García, Jean-Louis Pepin and Mario Cazzola. ERS Monograph, 2020

DATA: _____

FIRMA:  _____